WO2020007230A1 - Procédé et kit de détection de sinusite chronique avec un sous-type de polypes nasaux et l'application d'un gène ou d'une protéine clc en tant que biomarqueur - Google Patents

Procédé et kit de détection de sinusite chronique avec un sous-type de polypes nasaux et l'application d'un gène ou d'une protéine clc en tant que biomarqueur Download PDF

Info

Publication number
WO2020007230A1
WO2020007230A1 PCT/CN2019/093299 CN2019093299W WO2020007230A1 WO 2020007230 A1 WO2020007230 A1 WO 2020007230A1 CN 2019093299 W CN2019093299 W CN 2019093299W WO 2020007230 A1 WO2020007230 A1 WO 2020007230A1
Authority
WO
WIPO (PCT)
Prior art keywords
clc
gene
nasal
rna
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2019/093299
Other languages
English (en)
Chinese (zh)
Inventor
张罗
王成硕
闫冰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Institute Of Otolaryngology
Beijing Tongren Hospital
Original Assignee
Beijing Institute Of Otolaryngology
Beijing Tongren Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810717444.5A external-priority patent/CN108707661B/zh
Priority claimed from CN201810719334.2A external-priority patent/CN108977510A/zh
Priority claimed from CN201811437289.8A external-priority patent/CN109709329A/zh
Application filed by Beijing Institute Of Otolaryngology, Beijing Tongren Hospital filed Critical Beijing Institute Of Otolaryngology
Publication of WO2020007230A1 publication Critical patent/WO2020007230A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Definitions

  • the present disclosure belongs to the technical field of biomedicine, and particularly relates to a kit for detecting chronic sinusitis with nasal polyp subtypes, the use of a CLC gene or protein as a biomarker, and a method for detecting the CLC gene or protein in exfoliated nasal cells. Method of expression.
  • CRSwNP Chronic rhinosinusitis with nasal polyps
  • CRSwNP is often accompanied by asthma and allergic rhinitis. It has been reported that 7% of asthma patients have CRSwNP and 26-48% of CRSwNP have asthma. The pathogenesis of CRSwNP is still uncertain.
  • CRSwNP can be divided into Eosinophilic (CRSwNP, ECRSwNP) and Nonosinophilic (CRSwNP, nonECRSwNP) according to the degree of eosinophil infiltration.
  • the clinical manifestations, medications and prognosis of the two are different.
  • the clinical symptoms of eosinophils are severe, mainly nasal congestion and decreased olfactory symptoms. Most patients have asthma, and the recurrence rate is higher.
  • the degree of eosinophil infiltration in nasal polyp tissue is most closely related to recurrence. When the percentage of cells in the tissue exceeds 27%, the risk of recurrence exceeds 90%.
  • the sensitivity of eosinophilic polyps to glucocorticoids is significantly higher than that of non-eosinophilic polyps.
  • the clinical symptoms of non-eosinophils are generally mild, and there is less chance of asthma, airway inflammation is lighter, and the postoperative recurrence rate is lower than that of eosinophils, and the response to macrolide therapy is good.
  • the western countries are mainly eosinophils, which mainly show TH2 inflammatory response, while the proportion of eosinophils and non-eosinophils in China is about half, and the non-eosinophils mainly show TH1 / TH17 is predominantly inflammatory.
  • the eosinophilic and non-eosinophilic types are significantly different in immunopathological types, clinical symptoms, drug response, and prognosis.
  • Different chronic sinusitis with nasal polyps have different inflammatory / pathological typing treatment strategies. Therefore, the identification of the pathological classification of chronic sinusitis with nasal polyps is particularly important.
  • the judgment of the two subtypes is mainly based on the staining of histopathological specimens after nasal mucosal biopsy, and the lack of non-invasive biological markers for differential diagnosis.
  • the patients were routinely treated with pathological specimens such as paraffin fixation, and then stained with hematoxylin and eosin, and then the tissue-infiltrated inflammatory cells were observed with a high-power microscope (mainly inflammatory cells include eosinophil , Neutrophils, lymphocytes, plasma cells) infiltration number for cell typing.
  • pathological specimens such as paraffin fixation
  • hematoxylin and eosin mainly inflammatory cells include eosinophil , Neutrophils, lymphocytes, plasma cells
  • the disadvantages of nasal mucosal biopsy are as follows: 1.
  • Tissue pathological section is more limited, it can only reflect the inflammatory status of the specimen at the location of the section, it can not reflect the overall view of the tissue, and may cause misdiagnosis. 6.
  • Each film requires manual counting by a pathologist, which is difficult to operate in batches.
  • the present disclosure provides a kit for detecting chronic sinusitis with nasal polyp subtypes, wherein the kit includes a specific primer for a CLC gene.
  • the present disclosure also provides an application of the CLC gene as a biomarker in the preparation of a product for detecting chronic sinusitis with nasal polyp subtypes.
  • the disclosure also provides a use of the CLC gene as a biomarker for detecting chronic sinusitis with nasal polyp subtypes.
  • the present disclosure also provides the use of the kit according to the present disclosure for detecting chronic sinusitis with nasal polyp subtypes.
  • the present disclosure also provides the use of a reagent for detecting CLC for detecting chronic sinusitis with nasal polyp subtypes.
  • the present disclosure also provides a method for detecting the expression level of CLC gene in nasal exfoliated cells, including the following steps: extracting RNA from nasal exfoliated cells, reverse transcription of total RNA into cDNA, and using quantitative polymerase chain reaction to convert CLC in cDNA Genes and internal reference genes were amplified by real-time fluorescent quantitative PCR using specific primers of the CLC gene and specific primers of the internal reference gene, respectively. The expression of the CLC gene was calculated based on the detection results of the amplified products.
  • the present disclosure also provides the application of the above method for detecting the expression amount of CLC gene in nasal exfoliated cells in the preparation of a kit for detecting a chronic sinusitis subtype with nasal polyps.
  • the present disclosure also provides a method for detecting a chronic sinusitis subtype with nasal polyps, which comprises detecting the amount of CLC gene expression in nasal exfoliated cells by the method described in the present disclosure.
  • the present disclosure also provides a method for detecting a chronic sinusitis subtype with nasal polyps, comprising detecting and detecting the expression of CLC gene in nasal exfoliated cells, preferably using the kit according to the present disclosure to detect the cavity exfoliated cells. CLC gene expression.
  • the present disclosure also proposes an ELISA kit for detecting chronic sinusitis with nasal polyp subtypes and a preparation method thereof.
  • An ELISA kit for detecting chronic sinusitis with nasal polyp subtypes comprising an enzyme-labeled plate coated with Charcoalden's crystal protein CLC antibody.
  • the present disclosure also proposes the use of CLC protein as a biomarker for detecting chronic sinusitis with nasal polyp subtypes.
  • the present disclosure also provides the use of the ELISA kit according to the present disclosure for detecting chronic sinusitis with nasal polyp subtypes.
  • the present disclosure also provides a method for detecting a chronic sinusitis subtype with nasal polyps, which comprises detecting the expression of CLC protein using the ELISA kit of the present disclosure.
  • the present disclosure also provides the use of a CLC gene or a CLC protein as a biomarker for detecting chronic sinusitis with nasal polyp subtypes.
  • the present disclosure also provides a method for preparing the above-mentioned ELISA kit for detecting chronic sinusitis with nasal polyp subtypes, including the following steps:
  • Step 1 Preparation of a CLC antibody coated with Charcoalden's crystal protein: dilute a mouse anti-human CLC monoclonal antibody with a phosphate buffered saline solution;
  • Step 2 Prepare the enzyme-labeled plate coated with Charcoalden's crystal protein CLC antibody: take the enzyme-labeled plate, add diluted mouse anti-human CLC monoclonal antibody to each well, discard the supernatant at 4 ° C overnight, and add the wash Wash the plate with liquid. Add blocking solution to each well. Discard the supernatant again and add washing liquid to wash the plate.
  • Step 3 Double dilution standard: Take the standard and add the standard dilution to prepare a standard with a concentration of Xng / mL. Take the standard with a concentration of Xng / mL for multiple dilution and then double dilution. The concentration is: Xng / mL, 0.5Xng / mL, 0.25Xng / mL, 0.625Xng / mL, 0.3125Xng / mL, 0.15625Xng / mL, 0.078125Xng / mL;
  • Step 4 Sample dilution: Take the sample to room temperature and perform gradient dilution treatment
  • Step 5 Sample loading: Take the enzyme-labeled plate coated with Charcoalden's crystal protein CLC antibody prepared in step 2, and add the diluted standard product from step 3 and the diluted product from step 4 to each well. Samples, at the same time set blank wells with diluted standard solution, add washing solution to wash plate after incubation;
  • Step 6 Prepare working solution of detection solution A: Take biotin-labeled human CLC antibody and dilute it to 1-10 ⁇ g / mL with standard diluent and add it to each well of the microplate. Cover the membrane and incubate and add the washing solution. Wash plate
  • Step 7 Prepare the working solution of detection solution B: Dilute to a concentration of 0.5 to 5 ⁇ g / mL of anti-biotin antibody-conjugated horseradish peroxidase using the standard diluent, add it to each well of the microplate, and cover the membrane. After incubation, add washing solution to wash the plate;
  • Step 8 Color development: Take TMB and add the same volume of 0.75% hydrogen peroxide to prepare a TBM substrate coloring solution and add it to each well of the microtiter plate.
  • the stop solution added to each well of the microtiter plate will be detected by using a microplate reader with a detection wavelength of 450nm and 550nm-570nm when the well with a standard concentration of Xng / mL changes from yellow to blue.
  • Reference wavelength colorimetry make a standard curve to calculate the sample concentration value.
  • FIG. 1 is a real-time fluorescent quantitative PCR amplification curve diagram of a CLC gene in a part of an experimental example of the present disclosure
  • FIG. 3 is a real-time fluorescent quantitative PCR amplification curve diagram of the CLC gene in another part of the experimental example of the present disclosure
  • FIG. 7 is a melting curve diagram of the real-time fluorescent quantitative PCR of the CLC gene in another part of the experimental example of the present disclosure.
  • FIG. 9 is an optional ROC curve for detecting chronic sinusitis with nasal polyp typing in Experimental Example 1 of the present disclosure.
  • FIG. 10 is a real-time fluorescence quantitative PCR amplification curve diagram of the CLC gene in the second part of the experimental example of the present disclosure.
  • FIG. 12 is a melting curve diagram of the real-time fluorescent quantitative PCR of the CLC gene in the second part of the experimental example of the present disclosure.
  • FIG. 13 is a melting curve diagram of real-time fluorescent quantitative PCR of CLC gene in another part of Experimental Example 2 of the present disclosure.
  • FIG. 15 is a melting curve diagram of real-time fluorescent quantitative PCR of CLC gene in Experimental Example 3 of the present disclosure.
  • FIG. 17 is a melting curve diagram of the real-time fluorescent quantitative PCR of CLC gene in Experimental Example 4 of the present disclosure.
  • FIG. 18 is a standard curve diagram of the results of the effect detection test of Examples 13-15 of the present invention.
  • primer refers to an oligonucleotide that is capable of specifically annealing to an RNA or DNA region site adjacent to a target sequence, and as appropriate under conditions Primer for DNA synthesis. It is usually single-stranded, which can be naturally occurring or synthetic.
  • a “primer” or “oligonucleotide primer” typically comprises a sequence between about 5 to about 50 nucleotides, more preferably about 10 to about 30 nucleotides, or more preferably about 15 to 25 cores Glycylic acid.
  • the term "upstream primer” as used herein generally binds to a region closer to the 5 ' end of the nucleic acid molecule.
  • the term “downstream primer” as used herein generally binds to a region closer to the 3 'end of the nucleic acid molecule relative to a region on the nucleic acid to be amplified.
  • the term “internal reference gene” generally refers to a gene that is expressed relatively constant in various tissues and cells, such as GAPDH gene in nasal polyp tissue or cells exfoliated from nasal mucosa, and is mainly used as a reference when detecting gene expression levels.
  • polymerase chain reaction is the amplification of a nucleic acid consisting of: the initial denaturation step of separating the strands of a double-stranded nucleic acid sample, followed by repeating (i) allowing the amplification primers to be specific to the flanking position of the target sequence Annealing step of thermal annealing; (ii) an extending step of extending primers in the 5 'to 3' direction to form an amplicon polynucleotide complementary to the target sequence, and (iii) denaturation causing separation of the amplicon from the target sequence step.
  • the above steps can be performed at different temperatures, preferably using an automatic thermal cycler.
  • Real-time quantitative PCR also known as quantitative PCR, or QPCR for short, refers to adding a fluorescent group to a PCR reaction system, and using fluorescence signal accumulation to monitor the entire PCR process in real time. Method for quantitative analysis of unknown template by standard curve.
  • Ct cycle threshold
  • Ct value generally refers to the number of cycles that a fluorescent signal undergoes when a fluorescent signal reaches a set threshold.
  • the terms “comprising,” “including,” “covering,” “including,” “containing,” “characterized by,” “having,” or any other variation thereof are intended to encompass non-exclusive inclusion. Meaning.
  • the upstream primer of the CLC gene is shown in SEQ ID NO: 2
  • the downstream primer of the CLC gene is shown in SEQ ID NO: 3.
  • the kit further includes specific primers for internal reference genes.
  • the internal reference gene is GAPDH
  • an upstream primer of the internal reference gene is shown in SEQ ID NO: 4
  • a downstream primer of the CLC gene is shown in SEQ ID NO: 5.
  • the kit further includes: a reagent for extracting RNA from nasal polyp tissue or detached cells from nasal mucosa; a reagent for reverse transcription of total RNA into cDNA; using quantitative polymerase chain reaction Reagent for performing real-time quantitative PCR reaction of CLC gene and internal reference gene in cDNA.
  • the reagent for reverse transcription of total RNA into cDNA includes: a reverse transcription mixture and deRNase and deDNase water;
  • the reagent for reverse transcription of the total RNA into cDNA includes: 1 ⁇ L to 40 ⁇ L of a reverse transcription mixed solution, and 0 ⁇ L to 160 ⁇ L of deRNase and deDNase water. Further preferably, the reagent for reverse transcription of total RNA into cDNA includes: 2 ⁇ L of a reverse transcription mixed solution, and 0 ⁇ L to 8 ⁇ L of deRNase and DNAse dehydrating water.
  • a reagent for performing a real-time fluorescent quantitative PCR reaction of a CLC gene and an internal reference gene in a cDNA by a quantitative polymerase chain reaction includes a PCR premix solution, double distilled water, machine fluorescence compensation, and a correction agent. , The upstream primer of the CLC gene, the downstream primer of the CLC gene, the upstream primer of the internal reference gene, and the downstream primer of the internal reference gene.
  • a reagent for performing a real-time fluorescent quantitative PCR reaction of the CLC gene and the internal reference gene in the cDNA by a quantitative polymerase chain reaction includes: 1 ⁇ L to 25 ⁇ L of a PCR premix, and 0 ⁇ L to 50 ⁇ L of a double-distillation Water, 0 ⁇ L ⁇ 2 ⁇ L machine fluorescence compensation and correction agent, 0.01 ⁇ 100 ⁇ M CLC gene upstream primer, 0.01 ⁇ 100 ⁇ M CLC gene downstream primer, 0.01 ⁇ 100 ⁇ M internal reference gene upstream primer, 0.01 ⁇ 100 ⁇ M internal reference gene Downstream primers; further preferably, the reagents for real-time fluorescent quantitative PCR reaction of CLC gene and internal reference gene in cDNA by quantitative polymerase chain reaction include: 5 ⁇ L of PCR premix, 0 ⁇ L to 10 ⁇ L of double distilled water, according to the total volume Make up to 10 ⁇ L with water, 0.2 ⁇ L machine fluorescence compensation and correction
  • the reagent for extracting RNA from nasal polyp tissue can be selected from the following two reagents.
  • the first type includes: RNA extraction solution, chloroform, isopropanol, 65% to 90% ethanol, RNase and DNAse-free water; among these, preferably, 0.1 mL to 20 mL of RNA extraction solution Trizol or RNAiso Blood or RNAiso Plus or other substances containing phenol, guanidine isothiocyanate, 8-hydroxyquinoline, guanidine isothiocyanate or ⁇ -mercaptoethanol, the Trizol or the RNAiso Blood or the RNAiso Plus Or 0.1 to 0.5 times the volume of the other substance containing phenol, guanidine isothiocyanate, 8-quinolinol, guanidine isothiocyanate, or ⁇ -mercaptoethanol, and 0.5 to 3 times the volume of the chloroform Isopropyl alcohol, 0.5 to 5 times the volume of isopropyl alcohol, 65% to 90% ethanol, and 0.01mL to 5mL of RNase and DNase water; further preferably
  • the reagent for extracting RNA from nasal polyp tissue includes: a cell lysate, a first buffer solution for removing impurities from the purification column to which RNA is adsorbed, and an impurity for removing impurities from the purification column to which RNA is adsorbed And saline second buffer solution and deRNase and DNase water;
  • the tool for extracting RNA from nasal polyp tissue includes an RNA purification column; wherein the reagent for extracting RNA from nasal polyp tissue also includes DNase
  • the reaction solution or the tool for extracting RNA from nasal polyp tissue also includes a genomic DNA adsorption column;
  • the DNase reaction solution includes a DNase buffer solution, a recombinant DNase, and a double-distilled water of deRNase.
  • the reagent for extracting RNA from nasal polyp tissue includes 0.1 mL to 2 mL of a cell lysate for lysing cells and inhibiting RNA degradation, and 0.1 mL to 0.7 mL of a first washing agent Buffer solution, 0.1 mL to 0.7 mL of second buffer solution for washing, 0.01 mL to 1 mL of RNase and DNAse-free water, 0 to 10 ⁇ L of genomic DNA-recombinant DNase, and 0 to 10 ⁇ L of genomic DNA DNase buffer solution, 20 to 100 ⁇ L of RNase-free double-distilled water
  • the tool for extracting RNA from nasal polyp tissue includes an RNA purification column; or 0.1 mL to 2 mL for lysing cells and inhibiting RNA degradation Cell lysate, 0.1 mL to 0.7 mL of first buffer for washing, 0.1 mL to 0.7 mL of second buffer for washing, 0.01 mL to 1
  • the reagent for extracting RNA from nasal polyp tissue includes 300 ⁇ L of a cell lysate for lysing cells and inhibiting RNA degradation, 500 ⁇ L of a first buffer for washing, and 600 ⁇ L for washing Second buffer solution, 0.02 mL of RNase and DNase-free water, 4 ⁇ L of genomic DNA-recombinant DNase, 5 ⁇ L of 10 ⁇ genomic DNA-removed DNase buffer, 41 ⁇ L of de-RNase double-distilled water,
  • the tool for extracting RNA from nasal polyp tissue includes an RNA purification column; or includes 300 ⁇ L of a cell lysate for lysing cells and inhibiting RNA degradation, 500 ⁇ L of a first buffer for washing, and 600 ⁇ L of a second buffer for washing 0.02 mL of RNase and DNase-free water.
  • the tools for extracting RNA from nasal polyp tissue include genomic DNA adsorption columns and RNA purification columns.
  • the nasal polyp tissue is nasal polyp tissue obtained from nasal pathological biopsy, or the nasal mucosa exfoliated cells are nasal polyp cells obtained by brushing or sticking to the surface of the nasal polyp.
  • a ⁇ Ct (Ct (CLC) -Ct (GAPDH)) analysis method is used to analyze the data result of the amplification product, and the limit value for comparison with the ⁇ Ct is 4.85.
  • the upstream primer of the CLC gene is shown in SEQ ID NO: 2
  • the downstream primer of the CLC gene is shown in SEQ ID NO: 3.
  • the internal reference gene is GAPDH
  • the upstream primer of the internal reference gene is shown in SEQ ID NO: 4
  • the downstream primer is shown in SEQ ID NO: 5.
  • the nasal cavity exfoliated cells are obtained by using a hair brush on the surface of the nasal polyp, and the hair brush after the nasal exfoliated cells are obtained is placed in a cell lysate and stored below 4 ° C.
  • the method for extracting RNA from exfoliated cells in the nasal cavity includes two methods, wherein the first method includes the following steps:
  • Step 1 Dissolve the nasal cavity exfoliated cells in 100-2000 ⁇ L of cell lysate, add an equal volume of ethanol, mix well and add it to the RNA purification column. After centrifugation, remove the filtrate from the collection tube. The RNA purification column is placed in a collection tube;
  • Step 2 Add 300 ⁇ L to 700 ⁇ L of the first buffer to the RNA purification column obtained in step 1, and centrifuge to remove the first filtrate; continue to add 400 ⁇ L to 800 ⁇ L of the second buffer to the RNA purification column, After centrifugation, the second filtrate was removed, and an RNA purification column was eluted to obtain RNA.
  • the method for extracting RNA from exfoliated cells in the nasal cavity further includes the following steps: adding 10 to 100 ⁇ L of a DNase reaction solution to the RNA purification column after removing the second filtrate, and After the standing treatment, 300 ⁇ L to 700 ⁇ L of the second buffer was added, and after centrifugation, the third filtrate was removed. After the RNA purification column was eluted, the purity of the RNA was measured using a spectrophotometer to obtain RNA.
  • the method for preparing the DNase reaction solution includes the following steps: taking a DNase buffer solution, a recombinant DNase, and double-distilled water from which the RNase is removed to obtain a DNase reaction solution.
  • the method for preparing the DNase reaction solution includes the following steps: 5 ⁇ L of 10 ⁇ DNase buffer solution, 4 ⁇ L of recombinant DNase, and 41 ⁇ L of RNase-free double-distilled water are mixed to obtain a DNase reaction solution.
  • the method for extracting RNA from nasal cavity exfoliated cells further includes the following steps: in step 1 After the nasal cavity exfoliated cells are dissolved in the cell lysate, they are first added to a genomic DNA adsorption column to take a filtrate, and then an equal volume of ethanol is added to the filtrate.
  • the method for extracting RNA from exfoliated cells in the nasal cavity further includes the following steps: adding an RNA purification column to be eluted and adding distilled water to remove RNA hydrolase Or diethyl pyrocarbonate treated water, left at room temperature, centrifuged, and eluted the RNA purification column, and measured the purity of the RNA using a spectrophotometer to obtain RNA.
  • step 1 uses a cell lysate that can rapidly break down nasal cells and inhibit nucleases released by nasal cells; using a genomic DNA adsorption column for removing genomic DNA; in step 2
  • the RNA purification column is used for enriching RNA; the collection tube is used for collecting the solution after removing the genomic DNA, the first buffer for removing impurities from the purification column to which the RNA is adsorbed, and the first buffer for removing impurities and salts from the RNA solution.
  • the first method for extracting RNA from exfoliated nasal cells includes the following steps:
  • Step 1 Dissolve the nasal cavity exfoliated cells in 300 ⁇ L of cell lysate, add an equal volume of 70% ethanol, and mix the solution evenly with a pipette; immediately add the mixed solution to the RNA purification column at 12000 rpm , Centrifuge for 1min, remove the filtrate, and place the RNA purification column in a 2mL collection tube;
  • Step 2 Add 500 ⁇ L of the first buffer to the RNA purification column obtained in step 1, centrifuge at 12,000 rpm for 30 s to remove the first filtrate; continue to add 600 ⁇ L of the second buffer to the RNA purification column, Centrifuge at 12000 rpm for 30 seconds to remove the second filtrate;
  • Step 3 Take 5 ⁇ L of 10 ⁇ DNase buffer, 4 ⁇ L of recombinant DNase, and 41 ⁇ L of RNase-free double-distilled water to obtain a DNase reaction solution. Add 50 ⁇ L of DNase to the RNA purification column after removing the second filtrate. The reaction solution was left at room temperature for 15 minutes, 350 ⁇ L of the second buffer solution was added, 12000 rpm, and centrifuged for 30 seconds to remove the third filtrate;
  • Step 4 Place the RNA purification column with the third filtrate removed in step 3 in a 1.5 mL RNA hydrolase-free collection tube. Add 50 ⁇ L of RNA hydrolase-free distilled water or 0.1% diethyl pyrocarbonate-treated water to the RNA purification column. After standing at room temperature for 5 minutes, 12000 rpm, centrifugation for 2 minutes, the RNA purification column was eluted, and the OD260 / OD280 ratio of the RNA solution was measured using a spectrophotometer to obtain an RNA of 1.7 to 2.1.
  • the method for extracting RNA from exfoliated cells in the nasal cavity includes the following steps:
  • Step 1 Take a genomic DNA adsorption column into a 2mL collection tube, dissolve the nasal cavity exfoliated cells in 100-2000 ⁇ L of cell lysate, and add it to the genomic DNA adsorption column. Take the filtrate, and add an equal volume of the filtrate to the filtrate. 70% ethanol, mixed well and added to the RNA purification column, 12000 rpm, centrifugation for 1min, the filtrate was removed, and the RNA purification column was placed in a 2mL collection tube;
  • Step 2 Add 500 ⁇ L of the first buffer to the RNA purification column obtained in step 1, centrifuge at 12,000 rpm for 30 s to remove the first filtrate; continue to add 600 ⁇ L of the second buffer to the RNA purification column, Centrifuge at 12000 rpm for 30 seconds to remove the second filtrate;
  • Step 3 Place the RNA purification column with the second filtrate removed in step 2 into a 1.5 mL RNA hydrolase-free collection tube. Add 50 ⁇ L of RNA hydrolase-free distilled water or 0.1% diethyl pyrocarbonate-treated water to the RNA purification column. After standing at room temperature for 5 minutes, 12000 rpm, centrifugation for 2 minutes, the RNA purification column was eluted, and the OD260 / OD280 ratio of the RNA solution was measured using a spectrophotometer to obtain an RNA of 1.7 to 2.1.
  • the second method for extracting RNA from nasal cavity exfoliated cells includes the following steps: adding 0.1 mL to 20 mL of RNA extraction solution to a centrifuge tube containing nasal cavity exfoliated cells for lysis 1. Add chloroform 0.1-0.5 times the volume of the RNA extraction solution after shaking, mix by shaking, leave it at room temperature, centrifuge the centrifuge tube, take the supernatant, and add 0.5-3 times the volume of chloroform.
  • Isopropyl alcohol stand still, centrifuge after mixing, discard the supernatant, retain the first precipitate, and add 0.5 to 5 times the volume of 65% to 90% ethanol of the isopropyl alcohol to the first precipitate, After washing, mix and centrifuge, discard the supernatant, and retain the second pellet; cover the centrifuge tube, centrifuge again, remove the supernatant, and continue to add 0.01 to 5 mL of RNase and DNAase to the centrifuge tube The second precipitate was dissolved in water, and the purity of the RNA was measured by a spectrophotometer to obtain RNA.
  • the RNA extraction solution is Trizol, RNAiso Blood, RNAiso Plus or other phenol, guanidinium isothiocyanate, 8-hydroxyquinoline, guanidine isothiocyanate, and ⁇ -mercapto group. Any one or several reagents in ethanol.
  • the second method for extracting RNA from nasal cavity exfoliated cells includes the following steps: adding 0.1 to 20 mL of RNA extraction solution to a centrifuge tube containing nasal cavity exfoliated cells for dissolution and shaking After that, let stand at room temperature for 3 ⁇ 7min; add 40 ⁇ L ⁇ 5mL of chloroform, shake and mix well, let stand at room temperature for 3 ⁇ 7min, centrifuge at 3 °C ⁇ 5 °C, 10000 ⁇ 14000r / min for 10 ⁇ 20min; take the supernatant 40 ⁇ L ⁇ 8mL Add equal volume of isopropanol, mix and let stand for 8 ⁇ 12min, centrifuge at 3 °C ⁇ 5 °C, 10000 ⁇ 14000r / min for 10 ⁇ 20min, discard the supernatant and keep the first precipitate; Add 65% to 90% ethanol with the same volume as isopropanol, and centrifuge at 7000 to 14000 r / min for 10
  • the second method for extracting RNA from nasal cavity exfoliated cells includes the following steps: After adding 1 mL of RNA extraction solution to a centrifuge tube containing nasal cavity exfoliated cells for dissolution and shaking, Let stand at room temperature for 5min; add 200 ⁇ L of chloroform, shake and mix, stand at room temperature for 5min, and centrifuge at 12,000r / min for 15min at 4 °C; take 200 ⁇ L of the supernatant, add 200 ⁇ L of isopropanol, and let stand for 10min at 4 °C The supernatant was discarded by centrifugation at 12000 r / min for 15 min, and the first pellet was retained; 75% ethanol with an equal volume of isopropyl alcohol was added to the first pellet, and centrifuged at 7500 r / min for 15 min at 4 ° C, and the supernatant was discarded.
  • RNA Retain the second pellet; cover the centrifuge tube, centrifuge at 7 ° C, 7500 r / min for 2 min, remove the supernatant, and leave to stand for 15 min, then add 50 ⁇ L of deRNase and deDNase to the centrifuge tube to dissolve in water
  • a ratio of OD260 / OD280 of the RNA solution is measured by a spectrophotometer to be 1.7 to 2.1 to obtain RNA.
  • the method for reverse transcription of total RNA into cDNA includes the following steps: taking 1 to 3 ⁇ L of the reverse transcription mixture, 0 to 10 ⁇ L of de-hydrolase distilled water and the extracted RNA at a temperature of 37 ° C. A reverse transcription reaction occurred under the conditions for 15 min, and then a reverse transcriptase inactivation reaction occurred at a temperature of 84 ° C to obtain a reverse transcription product cDNA.
  • the method for reverse transcription of total RNA into cDNA includes the following steps: taking 2 ⁇ L of the reverse transcription mixture, 8 ⁇ L of the deRNA hydrolase distilled water, and a total amount not exceeding 500 ng or The volume does not exceed 8 ⁇ L of total RNA, and the de-RNA hydrolase distilled water is used to make up to 10 ⁇ L.
  • the reverse transcription reaction is performed under the following conditions: at 37 ° C, a reverse transcription reaction is performed for 15 minutes; at 85 Under the condition of °C, the reverse transcriptase inactivation reaction was performed for 5 seconds; the product was left at 4 °C.
  • the reaction system can be scaled up according to requirements.
  • a 10 ⁇ L reaction system can use a maximum of 500 ng of total RNA. Those skilled in the art can choose according to actual needs.
  • the real-time quantitative PCR amplification includes the following steps:
  • Step 1 Prepare a real-time quantitative PCR reaction solution: include 1 ⁇ L to 25 ⁇ L of PCR premix, 0 ⁇ L to 10 ⁇ L of double distilled water to make up the total volume of water to 10 ⁇ L, 0 ⁇ L to 2 ⁇ L of machine fluorescence compensation and correction agent, 0.01 to 100 ⁇ M
  • Step 2 Real-time quantitative PCR detection using standard two-step PCR amplification standard program or three-step PCR amplification standard program;
  • Step 3 Calculate CLC gene expression.
  • a real-time PCR reaction solution is prepared: including 5 ⁇ L of a PCR premix, 2.8 ⁇ L of double distilled water to make up the total volume of water to 10 ⁇ L, 0.2 ⁇ L of the machine fluorescence compensation and correction agent, and 0.5 ⁇ L of the CLC gene.
  • the reaction conditions of the standard two-step PCR amplification procedure include the following steps: Stage 1: Pre-denaturation for 30 seconds at 95 ° C; Stage 2 PCR reaction: at 95 The reaction was carried out at a temperature of 15 ° C for 15 seconds, and at a temperature of 60 ° C for 60 seconds, followed by annealing and extension, and 40 cycles were performed.
  • the reaction conditions of the standard three-step PCR amplification procedure include the following steps: Stage 1: Pre-denaturation at 95 ° C for 2 minutes; Stage 2 PCR reaction: at 95 The reaction was performed at a temperature of 1 ° C for 1 minute, at 55 ° C for 1 minute, and at 72 ° C for 1 minute, and 40 cycles were thus performed. Finally, 72 ° C, annealed and extended for 7 minutes.
  • the reagent for detecting CLC includes a specific primer of the CLC gene, and preferably the upstream primer of the specific primer of the CLC gene is as shown in SEQ ID NO: 2; the CLC gene The downstream primers are shown in SEQ ID NO: 3.
  • the reagent for detecting CLC is selected from the group consisting of a primer, an antibody, an aptamer, a probe, or a combination thereof for CLC.
  • the detection of CLC gene level by fluorescent PCR method is used to detect chronic sinusitis with nasal polyp subtype.
  • the amount of CLC gene expression in nasal exfoliated cells is detected by fluorescent PCR.
  • chronic sinusitis with nasal polyp subtype is determined according to ⁇ Ct (Ct (CLC) -Ct (GAPDH)), Ct (CLC) is the Ct value of the CLC gene, and Ct (GAPDH) is Ct value of internal reference gene GAPDH.
  • the ⁇ Ct greater than or equal to 4.85 represents non-eosinophilic chronic sinusitis with nasal polyps, and the ⁇ Ct less than 4.85 represents eosinophilic chronic sinusitis with nasal polyps.
  • the CLC antibody coated with Charcoalden's crystal protein is a mouse anti-human CLC monoclonal antibody.
  • the coating amount of the Charcoalden crystal protein CLC antibody in each microwell of the microtiter plate is 0.1 to 1 ⁇ g.
  • the ELISA kit further includes Charcoalden's crystal protein CLC standard and dilutions thereof, TMB substrate coloring solution, detection solution A working solution, and detection solution B. Working fluid, stop solution and washing solution.
  • the standard is a recombinant CLC protein
  • the standard dilution solution includes Tween 20, bovine serum albumin, and a phosphate buffered saline solution;
  • the working solution of the detection solution A includes a biotin-labeled human CLC antibody diluted to a concentration of 1 to 10 ⁇ g / mL by using a standard diluent;
  • the working solution of the detection solution B includes an anti-biotin antibody-conjugated horseradish peroxidase diluted with a standard diluent to a concentration of 0.5 to 5 ⁇ g / mL;
  • the termination solution is sulfuric acid
  • the washing solution includes Tween 20 and a phosphate buffered saline solution.
  • the standard product is recombinant CLC protein, which can be obtained directly through outsourcing, and the outsourced manufacturer is Abcam;
  • the standard dilution solution includes 1% Tween 20 and 10% bovine serum white Protein phosphate buffered saline solution;
  • the working solution of the detection solution A includes a biotin-labeled human CLC antibody diluted to a concentration of 5 ⁇ g / mL by using a standard diluent;
  • the working solution of the detection solution B includes an anti-biotin antibody-conjugated horseradish peroxidase diluted to a concentration of 1.25 / mL by using a standard diluent;
  • the termination solution is 2N sulfuric acid
  • the washing solution includes a phosphate buffered saline solution containing 0.05% Tween 20.
  • a method for preparing an enzyme-labeled plate coated with Charcoalden's crystal protein CLC antibody comprises the steps of: diluting a mouse anti-human CLC monoclonal antibody with a phosphate buffered saline solution, Take the enzyme-labeled plate, add diluted mouse anti-human CLC monoclonal antibody to it, discard the supernatant at 4 ° C overnight, wash the plate, add blocking solution to each well, and discard the supernatant again and wash the plate.
  • the present disclosure provides a method for preparing the above-mentioned ELISA kit for detecting chronic sinusitis with nasal polyp subtypes, comprising the following steps:
  • Step 1 Preparation of a CLC antibody coated with Charcoalden's crystal protein: dilute a mouse anti-human CLC monoclonal antibody with a phosphate buffered saline solution;
  • Step 2 Prepare the enzyme-labeled plate coated with Charcoalden's crystal protein CLC antibody: take the enzyme-labeled plate, add diluted mouse anti-human CLC monoclonal antibody to each well, discard the supernatant at 4 ° C overnight, and add the wash Wash the plate with liquid. Add blocking solution to each well. Discard the supernatant again and add washing liquid to wash the plate.
  • Step 3 Double dilution standard: Take the standard and add the standard dilution to prepare a standard with a concentration of Xng / mL. Take the standard with a concentration of Xng / mL for multiple dilution and then double dilution. The concentration is: Xng / mL, 0.5Xng / mL, 0.25Xng / mL, 0.625Xng / mL, 0.3125Xng / mL, 0.15625Xng / mL, 0.078125Xng / mL;
  • Step 4 Sample dilution: Take the sample to room temperature and perform gradient dilution treatment
  • Step 5 Sample loading: Take the enzyme-labeled plate coated with Charcoalden's crystal protein CLC antibody prepared in step 2, and add the diluted standard product from step 3 and the diluted product from step 4 to each well. Samples, at the same time set blank wells with diluted standard solution, add washing solution to wash plate after incubation;
  • Step 6 Prepare working solution of detection solution A: Take biotin-labeled human CLC antibody and dilute it to 1-10 ⁇ g / mL with standard diluent and add it to each well of the microplate. Cover the membrane and incubate and add the washing solution. Wash plate
  • Step 7 Prepare the working solution of detection solution B: Dilute to a concentration of 0.5 to 5 ⁇ g / mL of anti-biotin antibody-conjugated horseradish peroxidase using the standard diluent, add it to each well of the microplate, and cover the membrane. After incubation, add washing solution to wash the plate;
  • Step 8 Color development: Take TMB and add the same volume of 0.75% hydrogen peroxide to prepare a TBM substrate coloring solution and add it to each well of the microtiter plate.
  • the stop solution added to each well of the microtiter plate will be detected by using a microplate reader with a detection wavelength of 450nm and 550nm-570nm when the well with a standard concentration of Xng / mL changes from yellow to blue.
  • Reference wavelength colorimetry make a standard curve to calculate the sample concentration value.
  • step two 100 ⁇ L of diluted mouse anti-human CLC monoclonal antibody is added to each well of the microtiter plate; the amount of cleaning solution added to each well is 300 ⁇ L ; The amount of blocking solution added to each well is 250 ⁇ L;
  • the standard is taken and a standard diluent is added to prepare a standard with a concentration of 20ng / mL, and the dilution concentration is 20fold / mL, 10 ng / mL, 5 ng / mL, 2.5 ng / mL, 1.25 ng / mL, 0.625 ng / mL, and 0.312 ng / mL multiple dilution standards.
  • the standard dilution solution includes a phosphate buffered saline solution containing 1% Tween 20 and 10% bovine serum albumin; and the blocking solution includes 2% Tween 20 and 2% Phosphate buffered saline solution of bovine serum albumin.
  • step 6 the biotin-labeled human CLC antibody is diluted to 5 ⁇ g / mL with a standard dilution solution, and then 100 ⁇ L is added to each well of the microtiter plate, and Membrane and incubate at 37 ° C for 1 hour, and wash the plate 3 times;
  • step VII 100 ⁇ L is added to the microtiter plate after diluting the standard to a concentration of 1.25 ⁇ g / mL of anti-biotin antibody-conjugated horseradish peroxidase by using a standard diluent. In each well, cover the membrane and incubate at 37 ° C for 0.5 hours, and wash the plate 5 times;
  • step eight the amount of the TBM substrate coloring solution added to each well is 90 ⁇ L; the amount of the stop solution added to each well is 50 ⁇ L.
  • the chronic sinusitis with nasal polyp subtype is non-eosinophilic chronic sinusitis with nasal polyps or eosinophilic chronic sinusitis with nasal polyps.
  • the present disclosure provides a kit for detecting chronic sinusitis with nasal polyp subtypes.
  • the proteomics and transcriptomics methods are used to screen the CLC gene as a biomarker and apply it to the kit to achieve
  • a kit is used to detect chronic sinusitis with nasal polyp subtypes, so that the final obtained kit includes specific primers for the CLC gene.
  • the kit of the present disclosure can quickly identify nasal polyp subtypes, and is more accurate than traditional pathological detection methods.
  • the kit can simultaneously perform large-scale, rapid Testing, saving labor costs and medical treatment costs. And the systematic kit has high identification accuracy, which can fully reflect the histopathological characteristics.
  • the kit provided by the present disclosure can detect nasal polyp cells from the surface of the nasal polyp by brushing or sticking, so as to determine the chronic sinusitis of the patient with nasal polyp subtypes, avoiding causing the patient
  • the wound surface improves the safety of patient examination, and the operation is more convenient, saving labor costs and medical treatment costs.
  • the method for detecting the expression level of CLC gene in nasal cavity exfoliated cells provided by the present disclosure, using the effectively screened CLC gene as a biomarker, and providing a method for detecting the gene expression level, thereby realizing the expression of CLC gene in nasal cavity exfoliated cells.
  • the calculation can effectively obtain the expression level of CLC gene, and the provided method is simple and fast, high sensitivity, good reproducibility, and suitable for wide application.
  • the method for detecting the expression of CLC gene in nasal exfoliated cells provided by the present disclosure, wherein the CLC gene is a lysophospholipase expressed in eosinophils and basophils. It hydrolyzes lysophosphatidylcholine into glycerophosphocholine and free fatty acids.
  • the protein may have carbohydrate or IgE binding activity. It is structurally and functionally related to the galectin family of ⁇ -galactoside-binding proteins. It is related to inflammation and some myeloid leukemias. Diseases associated with CLC include autoinflammation, dyslipidemia, and dermatological syndrome.
  • the disclosed method for the expression of CLC gene in nasal exfoliated cells can be used to detect the expression of CLC in nasal exfoliated cells.
  • the method for detecting the expression level of CLC gene in exfoliated nasal cavity cells adopts a relative quantitative method of ⁇ Ct or 2- ⁇ Ct method according to actual needs, and selects a reference gene with a relatively constant expression level, and standardizes the number of reference genes Calculate the expression of the target gene by measuring the difference between the Ct value of the sample target gene and the internal reference gene.
  • the method is simple and fast, the detection accuracy is high, the detection cost can be reduced, and the detection time can be saved. The result is easy to interpret and so on. Greatly improved the experimental efficiency.
  • the method for detecting the expression level of CLC gene in exfoliated nasal cavity cells provides a basis for future gene screening technology for chronic sinusitis subtypes with nasal polyps, and provides a reliable guide for clinical guidance and drug treatment. basis.
  • the feasibility of the kit for detecting chronic sinusitis subtype with nasal polyps in clinical application is guaranteed.
  • chronic sinusitis with nasal polyp subtype is detected by detecting CLC protein levels in nasal lesion tissue of sinusitis with nasal polyps.
  • the ELISA kit for detecting chronic rhinosinusitis with nasal polyp subtypes provided by the present invention and a preparation method thereof, using a mouse anti-human CLC monoclonal antibody, which is applied to the ELISA kit to realize detection of chronic sinusitis with nasal
  • this kit can quickly identify nasal polyp subtypes, and is more accurate than traditional pathological detection methods.
  • This ELISA kit can perform large-scale and rapid detection of samples at the same time, saving manpower Cost and medical costs.
  • the present invention provides an ELISA kit for detecting chronic sinusitis with nasal polyp subtypes.
  • CLC protein as a marker for the detection of chronic sinusitis with nasal polyp subtypes has a unique advantage. This is because the protein level can reflect the final expression level, and the detection of the protein level provides the possibility to evaluate the efficacy based on the protein level.
  • the invention provides an ELISA kit for detecting chronic sinusitis with nasal polyp subtypes. By using a mouse anti-human CLC monoclonal antibody, the accuracy of detection of chronic sinusitis with nasal polyp subtypes is improved, and the rapidity is achieved. The effect of detection.
  • the present invention provides an ELISA kit for detecting chronic sinusitis with nasal polyp subtypes, which can comprehensively reflect the histopathological characteristics, solve the effect of human error in the prior art, and avoid the tissue section reflecting the local characteristics of the tissue Disadvantages of misdiagnosis. Rapid, accurate, and comprehensive identification of nasal polyp subtypes by ELISA kits is essential for clinical diagnosis and treatment. Early targeted treatment based on inflammatory subtypes of nasal polyps can effectively guide drug treatment for patients with chronic sinusitis and nasal polyps. The methods and surgical methods are determined to accurately predict the response to drug treatment and judge the prognostic effect.
  • a nasal cavity tissue sample of chronic sinusitis with nasal polyps is obtained by, for example, nasal endoscopy, and the protein level of CLC in the sample is determined by, for example, immunohistochemistry.
  • an anti-CLC antibody is used to determine the protein level of CLC in a sample.
  • the use of an antibody against CLC is provided for the detection of chronic sinusitis with nasal polyp subtypes.
  • kits for detecting chronic sinusitis with nasal polyp subtype includes a specific primer for a CLC gene.
  • the present disclosure obtains a kit for detecting chronic sinusitis with nasal polyp subtypes by using the CLC gene as a biomarker through proteomics and transcriptomics screening through a large number of creative experiments, which has not yet been provided in the existing technology. Any reports accordingly.
  • the CLC gene is a known gene, the gene ID is 1178, the DNA sequence is shown in SEQ ID NO: 1, and the gene NM number is 001828.5.
  • the upstream primer of the CLC gene is shown in SEQ ID NO: 2
  • the downstream primer of the CLC gene is shown in SEQ ID NO: 3.
  • the kit further includes a reference gene. More preferably, the internal reference gene is GAPDH, an upstream primer of the internal reference gene is shown in SEQ ID NO: 4, and a downstream primer of the CLC gene is shown in SEQ ID NO: 5.
  • the upstream primer and the downstream primer of the internal reference gene determined by the kit of the present disclosure can effectively obtain an appropriate ⁇ CT value by displaying the expression of the CLC gene compared to GAPDH when identifying the nasal polyp subtype of the kit of the present disclosure. Identification of nasal polyp subtypes. And has a higher accuracy.
  • the kit further comprises: a reagent for extracting RNA from nasal polyp tissue or detached cells from nasal mucosa; a reagent for reverse transcription of total RNA into cDNA; and a quantitative polymerase chain reaction for converting cDNA Reagent for CLC gene and internal reference gene for real-time quantitative PCR reaction.
  • the reagent for reverse transcription of total RNA into cDNA includes: a reverse transcription mixed solution and de-RNase and de-DNase water; using a quantitative polymerase chain reaction to perform real-time CLC genes and internal reference genes in cDNA
  • the reagents for the quantitative PCR reaction include: PCR premix, double-distilled water, machine fluorescence compensation and correction agent, CLC gene upstream primer, CLC gene downstream primer, internal reference gene upstream primer, and internal reference gene downstream primer.
  • RNA extraction solution chloroform, isopropanol, 65% to 90% ethanol, RNase and DNA. Enzyme water
  • the reagent for extracting RNA from nasal polyp tissue includes: a cell lysate, a first buffer solution for removing impurities from the purification column to which RNA is adsorbed, and an impurity for removing impurities from the purification column to which RNA is adsorbed And saline second buffer solution and deRNase and DNase water;
  • the tool for extracting RNA from nasal polyp tissue includes an RNA purification column; wherein the reagent for extracting RNA from nasal polyp tissue also includes DNase
  • the reaction solution or the tool for extracting RNA from nasal polyp tissue also includes a genomic DNA adsorption column;
  • the DNase reaction solution includes a DNase buffer solution, a recombinant DNase, and a double-distilled water of deRNase.
  • the reagent for reverse transcription of total RNA into cDNA includes: 1 ⁇ L to 40 ⁇ L of a reverse transcription mixed solution, and 0 ⁇ L to 160 ⁇ L of deRNase and DNAse dehydrating water.
  • the reagent for reverse transcription of the total RNA into cDNA includes: 2 ⁇ L of a reverse transcription mixed solution, and 0 ⁇ L to 8 ⁇ L of deRNase and DNAase water (completed to 8 ⁇ L with water according to the amount of RNA).
  • the reverse transcription step can be realized, and for those skilled in the art, it can be selected according to actual needs.
  • the reagents for real-time fluorescent quantitative PCR reaction of CLC gene and internal reference gene in cDNA by quantitative polymerase chain reaction include: 1 ⁇ L to 25 ⁇ L PCR premix, 0 ⁇ L to 50 ⁇ L double-distilled water, 0 ⁇ L to 2 ⁇ L machine Fluorescence compensation and correction agent, 0.01 to 100 ⁇ M upstream primer of CLC gene, 0.01 to 100 ⁇ M downstream primer of CLC gene, 0.01 to 100 ⁇ M internal reference gene upstream primer, 0.01 to 100 ⁇ M internal reference gene downstream primer;
  • the reagent for real-time fluorescent quantitative PCR reaction of the CLC gene and the internal reference gene in the cDNA by quantitative polymerase chain reaction includes: 5 ⁇ L of a PCR premix, 0 ⁇ L to 10 ⁇ L of double distilled water (to be supplemented with water according to the total volume) To 10 ⁇ L), 0.2 ⁇ L machine fluorescence compensation and correction agent, 1 ⁇ M CLC gene upstream primer, 1 ⁇ M CLC gene downstream primer, 1 ⁇ M internal reference gene upstream primer, 1 ⁇ M internal reference gene downstream primer.
  • the steps of real-time quantitative PCR amplification of the CLC gene and the internal reference gene in the cDNA by quantitative polymerase chain reaction can be realized, and those skilled in the art can choose according to actual needs.
  • the following two reagents can be selected.
  • the first includes: 0.1 mL to 20 mL of RNA extraction solution Trizol or RNAiso, Blood or RNAiso Plus or other phenol, isothiocyanate Guanidine acid, 8-hydroxyquinoline, guanidine isothiocyanate, or ⁇ -mercaptoethanol, the Trizol or the RNAisoBlood or the RNAisoPlus or the other substances containing phenol, guanidine isothiocyanate, 8- Hydroxyquinoline, guanidine isothiocyanate, or ⁇ -mercaptoethanol are 0.1 to 0.5 times the volume of chloroform, 0.5 to 3 times the volume of isopropyl alcohol, and 0.5 to 5 times the volume of isopropyl alcohol. 65% to 90% ethanol, and 0.01mL to 5mL of RNase and DNase water;
  • Another type includes: 0.1 mL to 2 mL of a cell lysate for lysing cells and inhibiting RNA degradation, 0.1 mL to 0.7 mL of a first buffer for washing, 0.1 mL to 0.7 mL of a second buffer for washing, 0.01mL to 1mL of RNase and DNase-free water, 0 to 10 ⁇ L of genomic DNA-recombinant DNase, 0 to 10 ⁇ L of genomic DNA-removed DNase buffer, 20 to 100 ⁇ L of RNase-free double distillation Water
  • the tool for extracting RNA from nasal polyp tissue includes an RNA purification column; or includes 0.1 mL to 2 mL of a cell lysate for lysing cells and inhibiting RNA degradation, and 0.1 mL to 0.7 mL of a first buffer for washing 0.1 to 0.7 mL of a second buffer solution for washing, 0.01 to 1 mL of RNase and DNase water, and the tools for extract
  • the following two reagents can be selected, the first includes: 1 mL of RNA extraction solution Trizol or RNAiso Blood or RNAiso Plus or other phenol, guanidine isothiocyanate , 8-hydroxyquinoline, guanidine isothiocyanate or ⁇ -mercaptoethanol, 200 ⁇ L of chloroform, 200 ⁇ L of isopropanol, 200 ⁇ L of 65% to 90% ethanol by volume, and 0.02 mL of deRNase and DNAse-free water; the names of the RNA extraction solutions are Trizol, RNAiso Blood, and RNAiso Plus are all trade names.
  • Another type includes: 300 ⁇ L of cell lysate for lysing cells and inhibiting RNA degradation, 500 ⁇ L of first buffer for washing, 600 ⁇ L of second buffer for washing, 0.02 mL of RNase and DNase water 4 ⁇ L of genomic DNA-removing recombinant DNase, 5 ⁇ L of genomic DNA-removing DNase buffer, 41 ⁇ L of de-RNase double-distilled water, the tool for extracting RNA from nasal polyp tissue includes an RNA purification column; or includes 300 ⁇ L of cell lysate for lysing cells and inhibiting RNA degradation, 500 ⁇ L of first buffer for washing, 600 ⁇ L of second buffer for washing, 0.02 mL of RNase and DNase-free water, said from the nose
  • Tools for extracting RNA from polyp tissue include genomic DNA adsorption columns and RNA purification columns. For the above-mentioned limited numerical ranges, the steps of extracting RNA from nasal polyp tissue can be realized, and those skilled in the art can choose according to actual
  • the cell lysate described above is used to rapidly disrupt cells and inhibit the release of nucleases from cells.
  • the first buffer is used to remove impurities from the purification column to which RNA is adsorbed, and the second buffer is used to remove the RNA that is adsorbed.
  • the impurities and salts of the purification column, de-RNase and DNase-free water are used to dissolve the RNA.
  • reagents for extracting RNA from nasal polyp tissues were separately packaged .
  • the nasal polyp tissue is nasal polyp tissue obtained from nasal pathological biopsy, or the nasal mucosa exfoliated cells are nasal polyp cells obtained by brushing or sticking to the surface of the nasal polyp.
  • the brushing or sticking method is used to avoid wounds to the patient, improve the safety of patient examination, and make the operation more convenient, saving labor costs and medical treatment costs.
  • a ⁇ Ct (Ct (CLC) -Ct (GAPDH)) analysis method is used to analyze the data result of the amplification product, and the limit value for comparison with the ⁇ Ct is 4.85.
  • the defined value can make the kit provided by the present disclosure more than 80% accurate in detecting chronic sinusitis with nasal polyp subtypes.
  • An embodiment of the present disclosure also provides an application of the CLC gene as a biomarker in the preparation of a product for detecting chronic sinusitis with nasal polyp subtype.
  • the product may be a detection reagent, a chip or a kit.
  • An embodiment of the present disclosure provides a method for detecting the expression amount of CLC gene in nasal cavity exfoliated cells, comprising the steps of: extracting RNA from nasal cavity exfoliated cells, reverse transcription of total RNA into cDNA, and using quantitative polymerase chain reaction to convert the The CLC gene and the internal reference gene were amplified by real-time fluorescent quantitative PCR using specific primers of the CLC gene and specific primers of the internal reference gene, respectively, and the expression of the CLC gene was calculated based on the detection results of the amplified products.
  • the present disclosure uses proteomics and transcriptomics methods to screen a large number of creative experiments to obtain a subtype of chronic sinusitis with nasal polyps by calculating the expression of CLC genes, and provides a simple and reliable method for calculating the expression of CLC genes. , High accuracy. No corresponding reports have been provided in the existing technology.
  • the CLC gene is a known gene, the gene ID is 1178, the DNA sequence is shown in SEQ ID NO: 1, and the gene NM number is 001828.5.
  • the upstream primer of the CLC gene is shown in SEQ ID NO: 2
  • the downstream primer of the CLC gene is shown in SEQ ID NO: 3.
  • the design of the upstream and downstream primers of the CLC gene is more sensitive. When detecting the expression of the CLC gene, the results are more accurate and repeatable.
  • the internal reference gene is GAPDH
  • the upstream primer of the internal reference gene is shown in SEQ ID NO: 4
  • the downstream primer is shown in SEQ ID NO: 5.
  • the nasal cavity exfoliated cells are obtained by using a hair brush on the surface of the nasal polyps, and the hair brush after obtaining the nasal cavity exfoliated cells is placed in a cell lysate and stored below 4 ° C. Based on this method, the method of the present disclosure avoids wounds to patients, improves the safety of patient examination, and is more convenient to operate, saving labor costs and medical treatment costs.
  • the method for extracting RNA from exfoliated nasal cells includes two methods, wherein the first method includes the following steps:
  • Step 1 Dissolve the nasal cavity exfoliated cells in 100-2000 ⁇ L of cell lysate, add an equal volume of ethanol, mix well and add it to the RNA purification column. After centrifugation, remove the filtrate from the collection tube. The RNA purification column is placed in a collection tube;
  • Step 2 Add 300 ⁇ L to 700 ⁇ L of the first buffer to the RNA purification column obtained in step 1, and centrifuge to remove the first filtrate; continue to add 400 ⁇ L to 800 ⁇ L of the second buffer to the RNA purification column, After centrifugation, the second filtrate was removed, and an RNA purification column was eluted to obtain RNA.
  • the method for extracting RNA from exfoliated cells in the nasal cavity further comprises the following steps: adding 10 to 100 ⁇ L of a DNase reaction solution to the RNA purification column after removing the second filtrate, and after standing treatment, adding 300 ⁇ L ⁇ 700 ⁇ L of the second buffer solution, after centrifugation, remove the third filtrate, take the RNA purification column and elute the RNA purity using a spectrophotometer to obtain RNA;
  • the method for preparing the DNase reaction solution includes the following steps: a DNase buffer solution, a recombinant DNase, and double-distilled water from which the RNase is removed are mixed to obtain a DNase reaction solution.
  • the method for preparing the DNase reaction solution includes the following steps: 5 ⁇ L of 10 ⁇ DNase buffer solution, 4 ⁇ L of recombinant DNase, and 41 ⁇ L of RNase-free double-distilled water are mixed to obtain a DNase reaction solution.
  • the method for extracting RNA from nasal cavity exfoliated cells when the genome content is low or the starting amount of material is low when performing RNA extraction further includes the following steps: in step 1, the nasal exfoliated cells are lysed After the cell lysate is added to a genomic DNA adsorption column to take a filtrate, an equal volume of ethanol is added to the filtrate.
  • the method for extracting RNA from nasal cavity exfoliated cells further includes the following steps: adding an RNA purification column to be eluted and adding distilled water to remove RNA hydrolase or diethyl pyrocarbonate treatment After the water was left at room temperature, the RNA purification column was eluted by centrifugation, and the RNA purity was measured by a spectrophotometer to obtain RNA.
  • Step 1 uses a cell lysate that can rapidly break down nasal cells and inhibit nucleases released by nasal cells; genomic DNA adsorption columns are used to remove genomic DNA; RNA purification columns in step 2 are used to enrich RNA; The collection tube is used for collecting the solution after removing the genomic DNA, the first buffer solution for removing impurities in the purification column to which the RNA is adsorbed, and the second buffer solution for removing impurities and salts in the RNA solution.
  • the first method for extracting RNA from exfoliated nasal cells includes the following steps:
  • Step 1 Dissolve the nasal cavity exfoliated cells in 300 ⁇ L of cell lysate, add an equal volume of 70% ethanol, and mix the solution evenly with a pipette; immediately add the mixed solution to the RNA purification column at 12000 rpm , Centrifuge for 1min, remove the filtrate, and place the RNA purification column in a 2mL collection tube;
  • Step 2 Add 500 ⁇ L of the first buffer to the RNA purification column obtained in step 1, centrifuge at 12,000 rpm for 30 s to remove the first filtrate; continue to add 600 ⁇ L of the second buffer to the RNA purification column, Centrifuge at 12000 rpm for 30 seconds to remove the second filtrate;
  • Step 3 Take 5 ⁇ L of 10 ⁇ DNase buffer, 4 ⁇ L of recombinant DNase, and 41 ⁇ L of RNase-free double-distilled water to obtain a DNase reaction solution. Add 50 ⁇ L of DNase to the RNA purification column after removing the second filtrate. The reaction solution was left at room temperature for 15 minutes, 350 ⁇ L of the second buffer solution was added, 12000 rpm, and centrifuged for 30 seconds to remove the third filtrate;
  • Step 4 Place the RNA purification column with the third filtrate removed in step 3 in a 1.5 mL RNA hydrolase-free collection tube. Add 50 ⁇ L of RNA hydrolase-free distilled water or 0.1% diethyl pyrocarbonate-treated water to the RNA purification column. After standing at room temperature for 5 minutes, 12000 rpm, centrifugation for 2 minutes, the RNA purification column was eluted, and the OD260 / OD280 ratio of the RNA solution was measured using a spectrophotometer to obtain an RNA of 1.7 to 2.1.
  • the method for extracting RNA from exfoliated nasal cells includes the following steps:
  • Step 1 Take the genomic DNA adsorption column in a 2mL collection tube, dissolve the nasal cavity exfoliated cells in 100-2000 ⁇ L of cell lysate, and add it to the genomic DNA adsorption column. Take the filtrate and add an equal volume of 70% ethanol, mixed well and added to the RNA purification column, 12000 rpm, centrifugation for 1min, the filtrate was removed, and the RNA purification column was placed in a 2mL collection tube;
  • Step 2 Add 500 ⁇ L of the first buffer to the RNA purification column obtained in step 1, centrifuge at 12,000 rpm for 30 s to remove the first filtrate; continue to add 600 ⁇ L of the second buffer to the RNA purification column, Centrifuge at 12000 rpm for 30 seconds to remove the second filtrate;
  • Step 3 Place the RNA purification column with the second filtrate removed in step 2 into a 1.5 mL RNA hydrolase-free collection tube. Add 50 ⁇ L of RNA hydrolase-free distilled water or 0.1% diethyl pyrocarbonate-treated water to the RNA purification column. Leave at room temperature for 5 minutes, 12000 rpm, centrifuge for 2 minutes, elute the RNA purification column, and use a spectrophotometer to measure the OD260 / OD280 ratio of the RNA solution from 1.7 to 2.1 to obtain RNA.
  • step 1 uses a cell lysate to rapidly break down nasal cells and inhibit nuclease released by nasal cells;
  • step 1 uses a genomic DNA adsorption column to remove genomic DNA; and an RNA purification column in step 2 is used for enrichment RNA;
  • the collection tube is used to collect the solution after removing the genomic DNA, the first buffer is used to remove impurities from the purification column to which the RNA is adsorbed, and the second buffer is used to remove impurities and salts from the RNA solution.
  • the second method for extracting RNA from nasal cavity exfoliated cells includes the following steps: adding 0.1 mL to 20 mL of RNA extraction solution to a centrifuge tube containing nasal cavity exfoliated cells, lysing, shaking and adding 0.1 to 0.5 times the volume of the chloroform of the RNA extraction solution, shake and mix, and stand at room temperature, centrifuge the centrifuge tube, take the supernatant, and add 0.5 to 3 times the volume of chloroform in isopropyl alcohol.
  • RNA purity is measured by a spectrophotometer to obtain RNA.
  • the RNA extraction solution is any one or more of Trizol, RNAisoBlood, RNAisoPlus or other phenol, guanidine isothiocyanate, 8-hydroxyquinoline, guanidine isothiocyanate and ⁇ -mercaptoethanol.
  • Trizol Trizol
  • RNAisoBlood RNAisoPlus or other phenol
  • guanidine isothiocyanate 8-hydroxyquinoline
  • guanidine isothiocyanate and ⁇ -mercaptoethanol.
  • reagents are examples of Trizol, RNAisoBlood, RNAisoPlus or other phenol, guanidine isothiocyanate, 8-hydroxyquinoline, guanidine isothiocyanate and ⁇ -mercaptoethanol.
  • the second method for extracting RNA from nasal cavity exfoliated cells includes the following steps: adding 0.1 to 20 mL of RNA extraction solution to a centrifuge tube containing nasal exfoliated cells for dissolution, shaking, and room temperature Let stand for 3 ⁇ 7min; add 40 ⁇ L ⁇ 5mL of chloroform, shake and mix well, let stand at room temperature for 3 ⁇ 7min, centrifuge at 3 °C ⁇ 5 °C, 10000 ⁇ 14000r / min for 10 ⁇ 20min; take the supernatant 40 ⁇ L ⁇ 8mL, add etc.
  • the volume of isopropanol was mixed and left to stand for 8-12 minutes, centrifuged at 3 ° C to 5 ° C, 10,000 to 14000 r / min for 10 to 20 minutes, the supernatant was discarded, and the first precipitate was retained;
  • Propanol equal volume of 65% to 90% ethanol was centrifuged at 3 ° C to 5 ° C, 7000 to 14000r / min for 10 to 20min, the supernatant was discarded, and the second pellet was retained;
  • the centrifuge tube was tightly closed at 3 ° C ⁇ 5 ° C, centrifuge at 7000 ⁇ 14000r / min for 1 ⁇ 3min, remove the supernatant, and let stand for 10 ⁇ 20min, then continue to add 0.01 ⁇ 5mL of deRNase and deDNase water to the centrifuge tube to dissolve the second Precipitate and measure RNA purity using a spectrophotometer to obtain RNA.
  • the second method for extracting RNA from nasal cavity exfoliated cells includes the following steps: adding 1 mL of RNA extraction solution to a centrifuge tube containing nasal cavity exfoliated cells for dissolution, shaking, and standing at room temperature for 5 min; adding 200 ⁇ L of chloroform, Mix by shaking, let stand at room temperature for 5 minutes, and centrifuge at 12,000 r / min for 15 min at 4 ° C. Take the supernatant 200 ⁇ L, add 200 ⁇ L isopropanol, mix and let stand for 10 min, and centrifuge at 4 ° C for 15 min at 12000 r / min to discard the supernatant.
  • the method for reverse transcription of total RNA into cDNA includes the following steps: 1 to 3 ⁇ L of the reverse transcription mixed solution, 0 to 10 ⁇ L of de-hydrolase-distilled water and the extracted RNA undergo a reverse transcription reaction at a temperature of 37 ° C. After 15 min, a reverse transcriptase inactivation reaction occurred at a temperature of 84 ° C to obtain a reverse transcription product cDNA.
  • the method for reverse transcription of total RNA into cDNA includes the following steps: taking 2 ⁇ L of the reverse transcription mixture, 8 ⁇ L of the deRNA hydrolase distilled water, and a total amount not exceeding 500 ng or a volume not exceeding
  • the de-hydrolase enzyme distilled water is used to make up to 10 ⁇ L
  • the reverse transcription reaction is performed after gentle mixing, the conditions are as follows: at 37 ° C, the reverse transcription reaction is performed for 15 minutes; at 85 ° C, Under the conditions, an inactivation reaction of reverse transcriptase was performed for 5 seconds; the product was left at 4 ° C.
  • the real-time quantitative PCR amplification includes the following steps:
  • Step 1 Prepare a real-time quantitative PCR reaction solution: include 1 ⁇ L to 25 ⁇ L of PCR premix, 0 ⁇ L to 10 ⁇ L of double distilled water to make up the total volume of water to 10 ⁇ L, 0 ⁇ L to 2 ⁇ L of machine fluorescence compensation and correction agent, 0.01 to 100 ⁇ M
  • Step 2 Real-time quantitative PCR detection using standard two-step PCR amplification standard program or three-step PCR amplification standard program;
  • Step 3 Calculate CLC gene expression.
  • a real-time quantitative PCR reaction solution was prepared: including 5 ⁇ L of a PCR premix, 2.8 ⁇ L of double distilled water to make up a total volume of water to 10 ⁇ L, 0.2 ⁇ L of a machine fluorescence compensation and correction agent, and 0.5 ⁇ L of an upstream of the CLC gene.
  • Primer 0.5 ⁇ L of downstream primer of CLC gene, 0.5 ⁇ L of upstream primer of internal reference gene, 0.5 ⁇ L of downstream primer of internal reference gene, 1 ng / ⁇ L of said cDNA.
  • the reaction conditions of the standard two-step PCR amplification procedure include the following steps: first stage: pre-denaturing at 95 ° C for 30 seconds; second stage PCR reaction: at 95 ° C Under the conditions, the reaction is performed for 15 seconds, and the reaction is performed at 60 ° C for 60 seconds, and the annealing is extended, so that 40 cycles are performed;
  • the reaction conditions of the standard three-step PCR amplification procedure include the following steps: first stage: pre-denaturation at 95 ° C for 2 minutes; second stage PCR reaction: at 95 ° C, reaction for 1 minute, at The reaction is performed at 55 ° C for 1 minute, and at 72 ° C for 1 minute, so that 40 cycles are performed; finally, 72 ° C, 7 minutes of annealing and extension;
  • Relative quantification method using ⁇ CT method or 2- ⁇ Ct method selecting internal reference genes with relatively constant expression, normalizing with the number of internal reference genes, and calculating the target gene expression by measuring the difference between the Ct value of the target gene and the internal reference gene. It is simple and fast, and the detection accuracy is high, which can reduce the detection cost and save the detection time. The result is easy to interpret and so on. Greatly improved the experimental efficiency.
  • internal reference genes are genes that are more stable in vivo and usually do not change with disease and so on. Therefore, comparison with internal reference genes can reflect the relative abundance of target genes and internal reference genes . You can use ⁇ CT method. For different subjects, the expression of CLC and internal reference genes can be used 2- ⁇ Ct method.
  • An embodiment of the present invention provides an ELISA kit for detecting chronic sinusitis with nasal polyp subtype, comprising an enzyme-labeled plate coated with Charcoalden's crystal protein CLC antibody.
  • the coated Charcoalden's crystal protein CLC antibody is a mouse anti-human CLC monoclonal antibody.
  • the coating amount of the Charcoalden's crystal protein CLC antibody in each microwell of the microtiter plate is 0.1 to 1 ⁇ g. In order to further improve the sensitivity of the ELISA kit, the coating amount of the Charcoalden's crystal protein CLC antibody in each microwell of the microtiter plate is preferably 0.5 ⁇ g.
  • the standard is a recombinant CLC protein, wherein the recombinant CLC protein is directly purchased and purchased, and the purchaser may be Abcam;
  • the standard dilution solution includes Tween 20, bovine serum albumin, and a phosphate buffered saline solution;
  • the working solution of the detection solution A includes a biotin-labeled human CLC antibody diluted to a concentration of 1 to 10 ⁇ g / mL by using a standard diluent;
  • the working solution of the detection solution B includes a diluent of 0.5 to 5 ⁇ g / mL using a standard diluent.
  • Anti-biotin antibody-bound horseradish peroxidase; the termination solution is sulfuric acid; the washing solution includes Tween 20 and a phosphate buffered saline solution.
  • the standard dilution solution includes a phosphate buffered saline solution containing 1% Tween 20 and 10% bovine serum albumin;
  • the working solution of detection solution A includes a biotin-labeled human CLC antibody diluted to a concentration of 5 ⁇ g / mL by using a standard diluent; and the working solution of detection solution B includes an anti-biocide diluted to a concentration of 1.25 / mL by using a standard diluent.
  • Antibody-bound horseradish peroxidase; the termination solution is 2N sulfuric acid; the washing solution includes a phosphate buffered saline solution containing 0.05% Tween 20.
  • a method for preparing an enzyme-labeled plate coated with Charcoalden's crystal protein CLC antibody includes the following steps: dilute a mouse anti-human CLC monoclonal antibody with a phosphate buffered saline solution, and take the enzyme Add a diluted mouse anti-human CLC monoclonal antibody to the target plate, discard the supernatant at 4 ° C overnight, wash the plate, add blocking solution to each well, and discard the supernatant again and wash the plate.
  • a method for preparing the above ELISA kit for detecting chronic sinusitis with nasal polyp subtypes includes the following steps:
  • Step 1 Preparation of a CLC antibody coated with Charcoalden's crystal protein: dilute a mouse anti-human CLC monoclonal antibody with a phosphate buffered saline solution;
  • Step 2 Prepare the enzyme-labeled plate coated with Charcoalden's crystal protein CLC antibody: take the enzyme-labeled plate, add diluted mouse anti-human CLC monoclonal antibody to each well, discard the supernatant at 4 ° C overnight, and add the wash Wash the plate with liquid. Add blocking solution to each well. Discard the supernatant again and add washing liquid to wash the plate.
  • Step 3 Double dilution standard: Take the standard and add the standard dilution to prepare a standard with a concentration of Xng / mL. Take the standard with a concentration of Xng / mL for multiple dilution and then double dilution. The concentration is: Xng / mL, 0.5Xng / mL, 0.25Xng / mL, 0.625Xng / mL, 0.3125Xng / mL, 0.15625Xng / mL, 0.078125Xng / mL;
  • Step 4 Sample dilution: Take the sample to room temperature and perform gradient dilution treatment
  • Step 5 Sample loading: Take the enzyme-labeled plate coated with Charcoalden's crystal protein CLC antibody prepared in step 2, and add the diluted standard product from step 3 and the diluted product from step 4 to each well. Samples, at the same time set blank wells with diluted standard solution, add washing solution to wash plate after incubation;
  • Step 6 Prepare working solution of detection solution A: Take biotin-labeled human CLC antibody and dilute it to 1-10 ⁇ g / mL with standard diluent and add it to each well of the microplate. Cover the membrane and incubate and add the washing solution. Wash plate
  • Step 7 Prepare the working solution of detection solution B: Dilute to a concentration of 0.5 to 5 ⁇ g / mL of anti-biotin antibody-conjugated horseradish peroxidase using the standard diluent, add it to each well of the microplate, and cover the membrane. After incubation, add washing solution to wash the plate;
  • Step 8 Color development: Take TMB and add the same volume of 0.75% hydrogen peroxide to prepare a TBM substrate coloring solution and add it to each well of the microtiter plate.
  • the stop solution added to each well of the microtiter plate will be detected by using a microplate reader with a detection wavelength of 450nm and 550nm-570nm when the well with a standard concentration of Xng / mL changes from yellow to blue.
  • Reference wavelength colorimetry make a standard curve to calculate the sample concentration value.
  • the second step 100 ⁇ L of diluted mouse anti-human CLC monoclonal antibody was added to each well of the microtiter plate; the amount of washing solution was added to each well was 300 ⁇ L; the amount of blocking solution added to each well was 250 ⁇ L ;
  • the standard is taken and the standard diluent is added to prepare a standard with a concentration of 20ng / mL. Based on this, the dilution concentration is: 20ng / mL, 10ng / mL, 5ng / mL, 2.5ng / mL, 1.25 ng / mL, 0.625 ng / mL, and 0.312 ng / mL dilution standard.
  • the standard dilution solution includes a phosphate buffered saline solution containing 1% Tween 20 and 10% bovine serum albumin; and the blocking solution includes 2% Tween 20 and 2% bovine serum Phosphate buffered saline solution of albumin.
  • step 6 the biotin-labeled human CLC antibody is diluted to 5 ⁇ g / mL with a standard dilution solution, and then 100 ⁇ L is added to each well of the microtiter plate. Incubate at 37 ° C for 1 hour and wash the plate 3 times;
  • the standard diluent is used to dilute the anti-biotin antibody-conjugated horseradish peroxidase to a concentration of 1.25 ⁇ g / mL, and then 100 ⁇ L is added to each well of the microtiter plate. Incubate at 37 ° C for 0.5 hours and wash the plate 5 times;
  • the amount of the TBM substrate coloring solution added to each well is 90 ⁇ L; the amount of the stop solution added to each well is 50 ⁇ L.
  • a kit for detecting chronic sinusitis with nasal polyp subtypes comprising the following reagents:
  • RNA extraction solution Trizol or RNAiso Blood or RNAisoPlus or other products containing phenol, guanidine isothiocyanate, 8-hydroxyquinoline, guanidine isothiocyanate, ⁇ -mercaptoethanol, etc.
  • Substances that can rapidly disrupt cells and inhibit nucleases released by the cells 2mL of chloroform; 20mL of isopropanol; 40mL of 65-90% ethanol; 5mL of RNase and DNAse-free water;
  • Reagent for reverse transcription of extracted RNA into cDNA 40 ⁇ L of reverse transcription mixture (containing reverse transcription enzymes, RNase inhibitors, random 6-nucleotide primers, polythymine, T repeat oligonucleotides , Deoxyribonucleotide triphosphate mixture, buffer solution, etc.), 160 ⁇ L of RNase and DNAse-free water; RNase and DNAse-free water are used to complete the system, solubilize and dilute RNA;
  • Quantitative polymerase chain reaction reagent for real-time fluorescent quantitative PCR reaction of CLC gene and internal reference gene in cDNA 25 ⁇ L premix (containing enzymes and buffers required for PCR), 0-50 ⁇ L double-distilled water (based on total Make up the volume to 50 ⁇ L with water), 0 to 2 ⁇ L of dye (for fluorescence compensation and correction of the machine), 100 ⁇ M upstream primer of the CLC gene, 100 ⁇ M downstream primer of the CLC gene, 100 ⁇ M upstream primer of the internal reference gene, 100 ⁇ M
  • a kit for detecting chronic sinusitis with nasal polyp subtypes comprising the following reagents:
  • RNA extraction solution Trizol or RNAiso Blood or RNAiso Plus or other substances containing phenol, guanidine isothiocyanate, 8-hydroxyquinoline, guanidine isothiocyanate, ⁇ -mercaptoethanol, etc.
  • Substances that can rapidly disrupt cells and inhibit the release of nucleases from cells 0.2mL of chloroform; 0.2mL of isopropanol; 0.2mL of 65-90% ethanol; 0.05mL of RNase and DNAse-free water;
  • Reagent for reverse transcription of extracted RNA into cDNA 2 ⁇ L of reverse transcription mixture (containing the enzyme required for reverse transcription, RNase inhibitor, random 6 nucleotide primers, polythymine, T repeat oligonucleotide , Deoxyribonucleotide triphosphate mixture, buffer solution, etc.), 7 ⁇ L of RNase and DNAse-free water; of which RNase and DNAse-free water are used to complete the system, solubilize and dilute RNA;
  • Reagent for real-time fluorescent quantitative PCR reaction of CLC gene and internal reference gene in cDNA by quantitative polymerase chain reaction 5 ⁇ L of premix (containing enzymes and buffers required for PCR), 0 to 10 ⁇ L of double distilled water (based on total Make up the volume to 10 ⁇ L with water), 0 to 2 ⁇ L of dye (for fluorescence compensation and correction of the machine), 50 ⁇ M upstream primer of the CLC gene, 50 ⁇ M downstream primer of the CLC gene, 50 ⁇ M upstream reference gene of the primer, 50 ⁇ M
  • the downstream primer of the internal reference gene 5 ⁇ g positive control, 5 ⁇ g negative control, the positive control is a plasmid containing CLC, and the negative control is an empty plasmid (plasmid vector).
  • a kit for detecting chronic sinusitis with nasal polyp subtypes comprising the following reagents:
  • RNA extraction solution Trizol or RNAiso Blood or RNAiso Plus or other containing phenol, guanidine isothiocyanate, 8-hydroxyquinoline, guanidine isothiocyanate, ⁇ -mercaptoethanol And other substances that can rapidly break down cells and inhibit the nuclease released by the cells; 0.05mL of chloroform; 0.015mL of isopropanol; 0.0075mL of 65-90% ethanol; 0.01mL of RNase and DNase-free water ;
  • Reagent for reverse transcription of total RNA into cDNA 1 ⁇ L of reverse transcription mixture (containing enzymes required for reverse transcription, RNase inhibitors, random 6 nucleotide primers, polythymine, T repeat oligonucleotides, Deoxyribonucleotide triphosphate mixtures, buffers, etc.), 0-10 ⁇ L of RNase and DNAse-free water; RNase and DNAse-free water are used to complete the system, solubilize and dilute RNA;
  • Quantitative polymerase chain reaction reagent for real-time fluorescent quantitative PCR reaction of CLC gene and internal reference gene in cDNA 1 ⁇ L premix (containing enzymes and buffers required for PCR), 0-10 ⁇ L double-distilled water (based on total The volume is made up to 10 ⁇ L with water), 0 to 2 ⁇ L of dye (for fluorescence compensation and correction of the machine), 1 ⁇ M upstream primer of the CLC gene, 1 ⁇ M downstream primer of the CLC gene, 1 ⁇ M upstream primer of the internal reference gene, 1 ⁇ M
  • a kit for detecting chronic sinusitis with nasal polyp subtypes comprising the following reagents and tools:
  • Reagents for RNA extraction from nasal polyp tissue 100 ⁇ L of cell lysate (RL buffer with 50 x dithiothreitol (DTT)), genomic DNA adsorption column for removing genomic DNA, and for collecting and removing genomic DNA
  • RL buffer with 50 x dithiothreitol (DTT) genomic DNA adsorption column for removing genomic DNA
  • genomic DNA adsorption column for removing genomic DNA
  • genomic DNA adsorption column for removing genomic DNA
  • genomic DNA adsorption column for removing genomic DNA
  • genomic DNA for collecting and removing genomic DNA
  • a collection tube for the solution an RNA purification column for enriching RNA, 0.1 mL of a first buffer for removing impurities from the purification column to which the RNA is adsorbed, and 0.1 mL of a second buffer for removing impurities and salts from the RNA solution Solution, centrifuge tube for collecting RNA, 0.01 mL of RNase and DNase water for dissolving
  • Reagent for reverse transcription of total RNA into cDNA 1 ⁇ L of reverse transcription mixture (containing enzymes required for reverse transcription, RNase inhibitors, random 6 nucleotide primers, polythymine, T repeat oligonucleotides, Deoxyribonucleotide triphosphate mixtures, buffers, etc.), 0-10 ⁇ L of RNase and DNAse-free water; RNase and DNAse-free water are used to complete the system, solubilize and dilute RNA;
  • Reagent for real-time fluorescent quantitative PCR reaction of CLC gene and internal reference gene in cDNA by quantitative polymerase chain reaction 25 ⁇ L of premix (containing enzymes and buffers required for PCR), 0 to 10 ⁇ L of double-distilled water (based on total Make up the volume to 10 ⁇ L with water), 0 to 2 ⁇ L of dye (for fluorescence compensation and correction of the machine), 0.01 ⁇ M upstream primer of CLC gene, 0.01 ⁇ M downstream primer of CLC gene, 0.01 ⁇ M upstream of reference gene Primer, 0.01 ⁇ M downstream primer of the internal reference gene, 1 ⁇ g positive control, 1 ⁇ g negative control, the positive control is a plasmid containing CLC, and the negative control is an empty plasmid (plasmid vector).
  • a kit for detecting chronic sinusitis with nasal polyp subtypes comprising the following reagents and tools:
  • Reagent for RNA extraction from nasal polyp tissue 0.3 mL of cell lysate (RL buffer with 50 x dithiothreitol (DTT)), RNA purification column for enriching RNA, 0.5 mL for removing adsorbed The first buffer of impurities in the RNA purification column, 0.6 mL of the second buffer for removing impurities and salts from the RNA solution, 4 ⁇ L of genomic DNA-removing recombinant DNase, 5 ⁇ L of genomic DNA-removing DNase buffer 2.Centrifuge tube for collecting RNA, 0.05mL of RNase and DNase water for dissolving RNA;
  • Reagent for reverse transcription of total RNA into cDNA 2 ⁇ L of reverse transcription mixture (containing the enzyme required for reverse transcription, RNase inhibitor, random 6 nucleotide primers, polythymine, T repeat oligonucleotide, Deoxyribonucleotide triphosphate mixtures, buffers, etc.), 0-10 ⁇ L of RNase and DNAse-free water; RNase and DNAse-free water are used to complete the system, solubilize and dilute RNA;
  • Reagent for real-time fluorescent quantitative PCR reaction of CLC gene and internal reference gene in cDNA by quantitative polymerase chain reaction 5 ⁇ L of premix (containing enzymes and buffers required for PCR), 0 to 10 ⁇ L of double distilled water (based on total Make up the volume to 10 ⁇ L with water), 0 to 2 ⁇ L of dye (for fluorescence compensation and correction of the machine), 10 ⁇ mol / L CLC gene upstream primer, 10 ⁇ mol / L CLC gene downstream primer, 10 ⁇ mol / L internal reference
  • a kit for detecting chronic sinusitis with nasal polyp subtypes comprising the following reagents and tools:
  • Reagents for RNA extraction from nasal polyps 2 mL of cell lysate (RL buffer with 50 x dithiothreitol (DTT)), a genomic DNA adsorption column for removing genomic DNA, and after collecting and removing genomic DNA
  • RL buffer with 50 x dithiothreitol (DTT) 2 mL of cell lysate
  • DTT dithiothreitol
  • a collection tube for the solution an RNA purification column for enriching RNA, 0.7 mL of a first buffer for removing impurities from the purification column to which the RNA is adsorbed, and 0.7 mL of a second buffer for removing impurities and salts from the RNA solution Liquid, centrifuge tube for collecting RNA, 1 mL of RNase and DNase water for dissolving RNA;
  • Reagent for reverse transcription of total RNA into cDNA 2 ⁇ L of reverse transcription mixture (containing the enzyme required for reverse transcription, RNase inhibitor, random 6 nucleotide primers, polythymine, T repeat oligonucleotide, Deoxyribonucleotide triphosphate mixtures, buffers, etc.), 0 ⁇ 8 ⁇ L of RNase and DNase water (make up to 8 ⁇ L with water according to the amount of RNA); RNase and DNase-free water is used for replenishment. Uniform system, dissolve and dilute RNA;
  • Reagents for quantitative real-time PCR reaction of CLC gene and internal reference gene in cDNA by quantitative polymerase chain reaction 5 ⁇ L of premix (containing enzymes and buffers required for PCR), 0-10 ⁇ L of double distilled water (based on total The volume is made up to 10 ⁇ L with water), 0 to 2 ⁇ L of dye (for fluorescence compensation and correction of the machine), 1 ⁇ M upstream primer of the CLC gene, 1 ⁇ M downstream primer of the CLC gene, 1 ⁇ M upstream primer of the internal reference gene, 1 ⁇ M Downstream primers for the internal reference gene, 1 ⁇ g positive control, 1 ⁇ g negative control.
  • the manufacturer of the first buffer RWA buffer used was Takara Company, No. 9767; the manufacturer of the second buffer RWB buffer was Takara Company, No. 9767.
  • kits provided in Examples 1 to 6 of the present disclosure can all realize the detection of chronic rhinosinusitis with nasal polyp subtypes.
  • the following are specific test experiments of the kits for detecting chronic rhinosinusitis with nasal polyp subtypes:
  • nasal polyps were obtained under nasal endoscope. Nasal polyps were cut into tissues with a diameter of about 0.5 cm, immersed in RNA stabilization and storage solution (RNAlater), stored at 4 ° C for a short period of time, and then transferred to a storage temperature below -20 ° C for a long time.
  • RNA stabilization and storage solution RNAlater
  • Step 1 Weigh the tissue immersed in RNA stabilization and storage solution (RNAlater). Weigh about 0.01g of tissue into a magnetic beaded centrifuge tube, place it in liquid nitrogen, and grind it on a homogenizer. (3000r, 5min) (or manual grinding). Add 1mL Trizol to the test tube containing the tissue cells to dissolve it, collect it in a centrifuge tube, shake it thoroughly, and leave it at room temperature for 5 minutes; then add 200 ⁇ L of chloroform (trichloromethane) to the RNA extraction reagent group, and shake vigorously to mix. Let stand at room temperature for 5 minutes.
  • Step 2 12,000 rpm, 4 ° C, and centrifuge for 15 minutes.
  • Step 3 Take the supernatant to obtain a volume of about 200 ⁇ L, add it to a centrifuge tube, and add an equal amount (about 200 ⁇ L) of isopropanol to the above RNA extraction reagent group. After mixing, let stand for 10 minutes, 12000 rpm, and centrifuge at 4 ° C for 15 minutes. Discard the supernatant and retain the pellet.
  • Step 4 Add about 200 ⁇ L of 75% ethanol (equivalent to about 150 ⁇ L of absolute ethanol and 50 ⁇ L of DNase and RNase water) of the above-mentioned RNA extraction reagent group (equivalent to isopropanol) to wash the precipitate and mix. Centrifuge at 7500 rpm, 4 ° C for 15 minutes. Discard the supernatant and retain the pellet.
  • Step 5 Cap the centrifuge tube tightly and centrifuge at 7500 rpm and 4 ° C for 2 minutes.
  • Step 6 Open the lid, discard the supernatant, and leave it in a fume hood for 15 minutes.
  • Step 7 Add 0.02 mL of RNA hydrolase-free and DNA hydrolase-free (RNase-free and DNase-free) water-soluble precipitates to the above-mentioned RNA extraction reagent group.
  • Step 8 Measure the RNA concentration with a spectrophotometer, and the OD260 / OD280 ratio is between 1.7-2.1.
  • the reverse transcription reaction conditions are as follows:
  • the product was left at 4 ° C.
  • Stage 1 Pre-denaturation: 95 ° C, 30 seconds.
  • Phase 2 PCR reaction: 95 ° C, 15 seconds; 60 ° C, 1 minute annealing extension, for a total of 40 cycles; Phase 2: Melting curve: 60 ° C gradually rises to 95 ° C, the rate is 0.1 ° C / second, Collecting fluorescence;
  • Step 1 Judgment of quality control of the experiment: the positive control Ct value ⁇ 20 and the negative control Ct value> 38 are considered as valid experiments, otherwise the experiments are invalid
  • Step 2 Judgment of typing: The Ct value of the target gene minus the Ct value of the reference gene. According to the ROC curve, the optimal Ct value of CLC is 4.85. If the Ct value of CLC ⁇ 4.85, it is a non-eosinophil Cellular chronic sinusitis with nasal polyps; if the Ct value of CLC is ⁇ 4.85, it is a typical eosinophilic chronic sinusitis with nasal polyps.
  • Step 1 Add 1mL Trizol to the test tube containing the detached cells, dissolve it, shake it thoroughly, and let it stand at room temperature for 5 minutes, then add 200 ⁇ L of chloroform (trichloromethane), mix with vigorous shaking, and let it stand at room temperature for 5 minutes;
  • chloroform trichloromethane
  • Step 2 12,000 rpm, 4 ° C, and centrifuge for 15 minutes;
  • Step 3 Take the supernatant to obtain a volume of about 200 ⁇ L, add to the centrifuge tube, and add the same amount of isopropyl alcohol (about 200 ⁇ L) as chloroform. After mixing, let stand for 10 minutes, 12000 rpm, and centrifuge at 4 ° C for 15 minutes. Discard the supernatant and keep the pellet;
  • Step 4 Add approximately 200 ⁇ L of 75% ethanol (a mixture of approximately 150 ⁇ L of absolute ethanol and 50 ⁇ L of DNAse and RNAse water) to the RNA extraction reagent group (equivalent to isopropyl alcohol), and mix well. 7500 rpm, 4 ° C, centrifugation for 15 minutes, discard the supernatant and retain the pellet;
  • Step 5 Cap the centrifuge tube tightly at 7500 rpm, 4 ° C, and centrifuge for 2 minutes;
  • Step 6 Open the lid, discard the supernatant, and leave it in a fume hood for 15 minutes;
  • Step 7 Add 0.02 mL of RNA-hydrolase-free and DNA-hydrolase-free (RNase-free and DNase-free) water-soluble precipitates to the above-mentioned RNA extraction reagent group;
  • Step 8 Measure the RNA concentration with a spectrophotometer.
  • the OD260 / OD280 ratio is preferably 1.7 to 2.1.
  • Step 1 Place the genomic DNA adsorption column (genomic DNA Spinner Column) on a 2mL collection tube (Collection Tube);
  • Step 2 Transfer the lysate (cell lysate) containing the detached cells into a genomic DNA adsorption column;
  • Step 3 12,000 rpm, centrifuge for 1 minute
  • Step 4 Discard the genomic DNA adsorption column and retain the filtrate in the 2mL collection tube;
  • Step 5 Add 300 ⁇ L of 70% ethanol to the above step 4 (precipitation may occur at this time), and use a pipette to mix the solution uniformly;
  • Step 6 Immediately transfer all the mixed solution (including the precipitate) into an RNA purification column (containing a 2 mL collection tube);
  • Step 7 12,000 rpm, centrifuge for 1 minute, and discard the filtrate. Place the RNA purification column back into the 2mL collection tube;
  • Step 8 Add 500 ⁇ L of the first buffer (Buffer RWA) to the RNA purification column, 12,000 rpm, centrifuge for 30 seconds, and discard the filtrate;
  • Buffer RWA the first buffer
  • Step 9 Add 600 ⁇ L of the second buffer (Buffer RWB) to the RNA purification column, 12,000 rpm, centrifuge for 30 seconds, and discard the filtrate.
  • Buffer RWB buffer RWB
  • Step 10 Place the RNA purification column on a 1.5 mL RNAase-free collection tube (RNase Free Colletion Tube), and add 50 ⁇ L of RNA hydrolysis-free distilled water (RNase Free dH2O) or 0.1% to the center of the RNA purification column membrane. Diethyl pyrocarbonate (DEPC) treated water, and allowed to stand at room temperature for 5 minutes;
  • RNase Free Colletion Tube 1.5 mL RNAase-free collection tube
  • RNase Free dH2O RNA hydrolysis-free distilled water
  • DEPC Diethyl pyrocarbonate
  • Step 11 Centrifuge at 12,000 rpm and elute the RNA with RNase-free and DNase-free water for 2 minutes;
  • Step 12 Measure the RNA concentration with a spectrophotometer, and the OD260 / OD280 ratio is 2.0.
  • Step 1 Configure 45 ⁇ L of SYBR Green 1 pre-mixed solution; and ROX: 1.8 ⁇ L, mix and divide into 3 parts, respectively A.11.7 ⁇ L; B.11.7 ⁇ L; C.23.4 ⁇ L, add 1ng / Solution A was obtained from ⁇ L positive control, solution B was added to B with 1ng / ⁇ L negative control, and solution C was added from C with 2ng to obtain solution C (SYBR Green Green 1 premix and ROX are products of Takara Company, article number RR820A);
  • Step 2 Configure 8 groups of parallel holes
  • the first and second parallel wells solution A, specific primers for CLC gene, 3.8 ⁇ L sterilized double distilled water;
  • solution B specific primers for CLC gene, 3.8 ⁇ L sterilized double distilled water
  • Step 3 Seal the plate with clear plastic film, centrifuge, and perform the PCR operation.
  • Step 4 Two-step PCR standard procedure:
  • Stage 1 Pre-denaturation: 95 ° C, 30 seconds.
  • Phase 2 Phase 2: PCR reaction: 95 ° C, 15 seconds; 60 ° C, 1 minute annealing extension, 40 cycles were performed. ;
  • kits provided in Examples 1 to 6 of the present disclosure can all realize the detection of chronic rhinosinusitis with nasal polyp subtypes.
  • Example 5 the effect of the kit for detecting chronic rhinosinusitis with nasal polyp subtypes is performed as follows. Detection experiment:
  • RNA stabilization and storage solution RNAlater
  • Step 1 Weigh the tissue immersed in RNA stabilization and storage solution (RNAlater). Weigh about 0.01g of tissue into a magnetic beaded centrifuge tube, place it in liquid nitrogen, and grind it on a homogenizer. (3000r, 5min) (or manual grinding); add 0.3mL cell lysate, 12,000 rpm, centrifuge for 15 minutes
  • Step 2 Aspirate the supernatant, add 70% ethanol (70% absolute ethanol and 30% DEPC or RNase and DNase water) equal to the volume of the supernatant, and use a pipette to mix the solution uniformly;
  • Step 3 Transfer all the mixed solution (including the precipitate) to the RNA purification column (including the 2mL collection tube) immediately;
  • Step 4 12,000 rpm, centrifuge for 1 minute, and discard the filtrate. Put the RNA purification back into the 2mL collection tube;
  • Step 5 Add 500 ⁇ L of the first buffer solution (Buffer RWA) to the RNA purification column, 12,000 rpm, centrifuge for 30 seconds, and discard the filtrate;
  • Buffer RWA the first buffer solution
  • Step 6 Add 600 ⁇ L of a second buffer (Buffer RWB) to the RNA purification column, 12,000 rpm, centrifuge for 30 seconds, and discard the filtrate;
  • Buffer RWB a second buffer
  • Step 7 Preparation of DNase I reaction solution: Take 5 ⁇ L of 10 ⁇ DNase I buffer, 4 ⁇ L of recombinant DNase I ((RNase-free, 5U / ⁇ L), 41 ⁇ L of RNase-free Double distilled water into a new 1.5mL tube (no RNase) and mix well;
  • Step 8 Add 50 ⁇ L DNase I reaction solution to the center of the RNA purification column membrane, and leave it at room temperature for 15 minutes;
  • Step 9 Add 350 ⁇ L of a second buffer to the center of the RNA purification column membrane, 12,000 rpm, centrifuge for 30 seconds, and discard the filtrate;
  • Step 10 Repeat step 6;
  • Step 11 Reposition the RNA purification column on a 2mL collection tube, 12,000 rpm, and centrifuge for 2 minutes;
  • Step 12 Place the RNA purification column on a 1.5 mL RNAase-free collection tube (RNase Free Colletion Tube), and add 50 ⁇ L of RNAase-free distilled water (RNase Free HdO) or 0.1% to the center of the RNA purification column membrane. Diethyl pyrocarbonate (DEPC) treated water, and allowed to stand at room temperature for 5 minutes;
  • RNase Free Colletion Tube 1.5 RNAase-free collection tube
  • RNase Free HdO RNAase-free distilled water
  • DEPC Diethyl pyrocarbonate
  • Step 13 Centrifuge at 12,000 rpm, and elute RNA with RNase- and DNase-free water for 2 minutes;
  • Step 14 Measure the RNA concentration with a spectrophotometer, and the OD260 / OD280 ratio is 2.0;
  • reaction conditions used a standard three-step PCR amplification procedure:
  • Stage 1 Pre-denaturation: 95 ° C, 2 minutes;
  • Phase 2 Phase 2: PCR reaction: 95 ° C, 1 minute; 55 ° C, 1 minute, 72 ° C for 1 minute, a total of 40 cycles were performed, and finally 72 ° C, 7 minutes annealing extension.
  • the present disclosure provides a kit for detecting chronic sinusitis with nasal polyp subtypes.
  • the CLC gene is selected as a biomarker for screening and applied to the kit to realize the detection of chronicity by using the kit.
  • the method of sinusitis with nasal polyp subtypes can quickly, accurately and comprehensively identify patients with nasal polyp subtypes through the kit, in order to carry out targeted treatment based on the inflammatory subtypes of nasal polyps as soon as possible, and effectively guide chronic sinusitis.
  • the determination of drug treatment methods and surgical methods for patients with nasal polyps accurately predict the response to drug treatment, and judge the prognostic effect.
  • a method for detecting the expression of CLC gene in nasal exfoliated cells comprising the following steps:
  • Step 1 Extract RNA from exfoliated nasal cells:
  • Step 1 Take the genomic DNA adsorption column into a 2mL collection tube, dissolve the nasal cavity exfoliated cells in 300 ⁇ L of cell lysate, and add it to the genomic DNA adsorption column. Take the filtrate and add an equal volume of 70% to the filter. Ethanol, after mixing, added to the RNA purification column, 12000 rpm, centrifugation for 1min, the filtrate was removed, and the RNA purification column was placed in a 2mL collection tube;
  • Step 2 Add 500 ⁇ L of the first buffer to the RNA purification column obtained in step 1, centrifuge at 12,000 rpm for 30 s to remove the first filtrate; continue to add 600 ⁇ L of the second buffer to the RNA purification column, Centrifuge at 12000 rpm for 30 seconds to remove the second filtrate;
  • Step 3 Place the RNA purification column with the second filtrate removed in step 2 into a 1.5 mL RNA hydrolase-free collection tube. Add 50 ⁇ L of RNA hydrolase-free distilled water or 0.1% diethyl pyrocarbonate-treated water to the RNA purification column. Leave at room temperature for 5 minutes, 12000 rpm, centrifuge for 2 minutes, elute the RNA purification column, and use a spectrophotometer to measure the OD260 / OD280 ratio of the RNA solution to 2.0 to obtain RNA;
  • Step 2 Prepare cDNA by reverse transcription, including the following steps: take 2 ⁇ L of the reverse transcription mixture, 0-8 ⁇ L of the deRNA hydrolase distilled water (make up to 8 ⁇ L with water according to the amount of RNA), and the total amount does not exceed 500ng Or the total RNA volume is not more than 8 ⁇ L, and the de-RNA hydrolase distilled water is used to make up to 10 ⁇ L.
  • reverse transcription reaction is performed under the following conditions: at 37 ° C, a reverse transcription reaction is performed for 15 minutes; Under the condition of 85 ° C, the reverse transcriptase inactivation reaction was performed for 5 seconds; the product was left at 4 ° C.
  • Step 3 Real-time quantitative PCR amplification detection, including the following steps:
  • Step 1 Prepare a real-time quantitative PCR reaction solution: include 1 ⁇ L of PCR premix, 0-10 ⁇ L of double-distilled water (make up to 10 ⁇ L with water based on the total volume), 0.2 ⁇ L of machine fluorescence compensation and correction agent, 1 ⁇ M of CLC Gene upstream primer, 1 ⁇ M CLC gene downstream primer, 1 ⁇ M internal reference gene upstream primer, 1 ⁇ M internal reference gene downstream primer, 0.01 ⁇ L of the cDNA, 1 ⁇ g positive control, 1 ⁇ g negative control, positive control contains CLC plasmid, negative control is empty plasmid (plasmid vector);
  • Step 2 Standard procedure for two-step PCR amplification: The reaction conditions for the standard procedure for two-step PCR amplification include the following steps: Stage 1: Pre-denaturation for 30 seconds at 95 ° C; Stage 2 PCR reaction : Reaction was performed at 95 ° C for 15 seconds, and at 60 ° C, reaction was performed for 60 seconds, followed by annealing extension, and 40 cycles were performed.
  • Step 4 Calculate the expression level of the CLC gene:
  • a delta CT method is used to compare the difference in expression levels between CLC and an internal reference gene: the average CT value of CLC is 20.1, the average CT value of GAPDH is 18.9, and the delta CT value is 1.2.
  • a method for detecting the expression of CLC gene in nasal exfoliated cells comprising the following steps:
  • Step 1 Extract RNA from exfoliated nasal cells:
  • Step 1 Take the genomic DNA adsorption column into a 2mL collection tube, dissolve the nasal cavity exfoliated cells in 100 ⁇ L of cell lysate, add it to the genomic DNA adsorption column, centrifuge at 12000 rpm for 60s, and take the filtrate. Add an equal volume of 70% ethanol to the filter, mix it and add it to the RNA purification column, 12000 rpm, centrifuge for 1min, remove the filtrate, and place the RNA purification column in a 2mL collection tube;
  • Step 2 Add 300 ⁇ L of the first buffer to the RNA purification column obtained in step 1, centrifuge at 12,000 rpm for 30 seconds to remove the first filtrate; continue to add 400 ⁇ L of the second buffer to the RNA purification column Centrifuge at 12000 rpm for 30 seconds to remove the second filtrate;
  • Step 3 Place the RNA purification column with the second filtrate removed in step 2 into a 1.5 mL RNA hydrolase-free collection tube. Add 50 ⁇ L of RNA hydrolase-free distilled water or 0.1% diethyl pyrocarbonate-treated water to the RNA purification column. Leave at room temperature for 5 minutes, 12000 rpm, centrifuge for 2 minutes, elute the RNA purification column, and use a spectrophotometer to measure the OD260 / OD280 ratio of the RNA solution to 2.0 to obtain RNA;
  • Step 2 Reverse transcription to prepare cDNA, including the following steps: take 1 ⁇ L of the reverse transcription mixture, 0 to 10 ⁇ L of the deRNA hydrolase distilled water, and total RNA not exceeding 500 ng or 8 ⁇ L in volume. Make up the RNA hydrolase distilled water to make up to 10 ⁇ L; gently mix the reverse transcription reaction under the following conditions: at 37 ° C for 15 minutes, and at 85 ° C for 5 seconds Reverse transcriptase inactivation reaction; the product was left at 4 ° C.
  • Step 3 Real-time quantitative PCR amplification detection, including the following steps:
  • Step 1 Prepare a real-time quantitative PCR reaction solution: include 25 ⁇ L of PCR premix, 0 to 10 ⁇ L of double distilled water (to make up to 10 ⁇ L with water based on the total volume), and 0 to 2 ⁇ L of dye (for fluorescence compensation of the machine) And correction), 0.01 ⁇ M upstream primer for CLC gene, 0.01 ⁇ M downstream primer for CLC gene, 0.01 ⁇ M upstream reference gene for upstream primer, 0.01 ⁇ M downstream reference gene for primer, 5 ⁇ L cDNA, 1 ⁇ g positive control, 1 ⁇ g negative Control, the positive control is a plasmid containing CLC, and the negative control is an empty plasmid (plasmid vector);
  • Step 2 Standard procedure for two-step PCR amplification: The reaction conditions for the standard procedure for two-step PCR amplification include the following steps: Stage 1: Pre-denaturation for 30 seconds at 95 ° C; Stage 2 PCR reaction : Reaction was performed at 95 ° C for 15 seconds, and at 60 ° C, reaction was performed for 60 seconds, followed by annealing extension, and 40 cycles were performed.
  • Step 4 Calculate the expression level of the CLC gene:
  • ⁇ CT method was used to compare the expression of CLC and internal reference genes: the average CT value of CLC was 24.5, the average CT value of GAPDH was 18.0, and the ⁇ CT value was 6.5.
  • a method for detecting the expression of CLC gene in nasal exfoliated cells comprising the following steps:
  • Step 1 Extract RNA from exfoliated nasal cells:
  • Step 1 Take the genomic DNA adsorption column into a 2mL collection tube, dissolve the nasal cavity exfoliated cells in 2000 ⁇ L of cell lysate, add it to the genomic DNA adsorption column, centrifuge at 12000 rpm for 60 seconds, and take the filtrate. Add an equal volume of 70% ethanol to the filter, mix it and add it to the RNA purification column, 12000 rpm, centrifuge for 1min, remove the filtrate, and place the RNA purification column in a 2mL collection tube;
  • Step 2 Add 700 ⁇ L of the first buffer to the RNA purification column obtained in step 1, centrifuge at 12,000 rpm for 30 s to remove the first filtrate; continue to add 800 ⁇ L of the second buffer to the RNA purification column, Centrifuge at 12000 rpm for 30 seconds to remove the second filtrate;
  • Step 3 Place the RNA purification column with the second filtrate removed in step 2 into a 1.5 mL RNA hydrolase-free collection tube. Add 50 ⁇ L of RNA hydrolase-free distilled water or 0.1% diethyl pyrocarbonate-treated water to the RNA purification column. Leave at room temperature for 5 minutes, 12000 rpm, centrifuge for 2 minutes, elute the RNA purification column, and use a spectrophotometer to measure the OD260 / OD280 ratio of the RNA solution to 2.0 to obtain RNA;
  • Step 2 Reverse transcription to prepare cDNA, including the following steps: take 3 ⁇ L of the reverse transcription mixture, 0-8 ⁇ L of RNase and DNAse-free water (make up to 8 ⁇ L with water according to the amount of RNA), and the total amount does not exceed 500ng or total volume of no more than 8 ⁇ L, the deRNA hydrolase distilled water was made up to 10 ⁇ L; the reverse transcription reaction was performed after gentle mixing, the conditions were as follows: at 37 ° C, a reverse transcription reaction was performed for 15 minutes; Under the condition of 85 ° C, the reverse transcriptase inactivation reaction was performed for 5 seconds; the product was left at 4 ° C.
  • Step 3 Real-time quantitative PCR amplification detection, including the following steps:
  • Step 1 Prepare a real-time PCR reaction solution: include 5 ⁇ L of premixed solution (containing enzymes and buffers required for PCR), 0-10 ⁇ L of double-distilled water (make up to 10 ⁇ L with water based on the total volume), and 0 to 2 ⁇ L of Dye (for fluorescence compensation and correction of the machine), 1 ⁇ M upstream primer for CLC gene, 1 ⁇ M downstream primer for CLC gene, 1 ⁇ M upstream reference gene for primer, 1 ⁇ M downstream reference gene for primer, 2 ⁇ L cDNA, 1 ⁇ g Positive control, 1 ⁇ g negative control;
  • Step 2 Standard procedure for two-step PCR amplification: The reaction conditions for the standard procedure for two-step PCR amplification include the following steps: Stage 1: Pre-denaturation for 30 seconds at 95 ° C; Stage 2 PCR reaction : Reaction was performed at 95 ° C for 15 seconds, and at 60 ° C, reaction was performed for 60 seconds, followed by annealing extension, and 40 cycles were performed.
  • Step 4 Calculate the expression level of the CLC gene:
  • ⁇ CT method was used to compare the expression of CLC and internal reference genes.
  • the average CT value of CLC was 24.0
  • the average CT value of GAPDH was 17.9
  • the ⁇ CT value was 6.1.
  • the preferred manufacturer of the first buffer RWA buffer used is Takara Company, article number 9767; the manufacturer of the second buffer RWB buffer is Takara Company, article number 9767.
  • the protection scope of the present application is not limited to the first buffer solution and the second buffer solution described above. Those skilled in the art can choose according to the actual application needs.
  • nasal endoscope was used to press the surface of the nasal polyps with a brush (Copan) for 30 seconds, rotated 3-4 times to brush the surface of the polyp, and the brush was placed in a subsequent place.
  • the lysate is stored at 4 ° C for short-term storage (no more than 24 hours), or transferred to long-term storage below -20 ° C.
  • a method for detecting the expression of CLC gene in nasal exfoliated cells comprising the following steps:
  • Step 1 Extract RNA from exfoliated nasal cells: add 1mL RNA extraction solution to the centrifuge tube containing detached nasal cells, dissolve and shake, and let stand at room temperature for 5min; add 200 ⁇ L of chloroform, mix by shaking, and let stand at room temperature for 5min. Centrifuge at 12000 r / min for 15 min at 4 ° C. Take 200 ⁇ L of the supernatant, add 200 ⁇ L isopropanol, mix and let stand for 10 min. Centrifuge at 4 ° C, 12000 r / min for 15 min. Discard the supernatant and retain the first pellet.
  • Step 2 The steps for preparing cDNA by reverse transcription are the same as in Example 7.
  • Step 3 The detection steps of real-time quantitative PCR amplification are the same as those in Example 7.
  • Step 4 Calculate the expression level of the CLC gene:
  • Step 1 Calculate the average ⁇ CT of the healthy control group:
  • subjects 1 to 10 are healthy control groups.
  • Step 2 Calculate the relative expression of the subject:
  • the patient was instructed to flush the nasal cavity with normal saline, and under a nasal endoscope, press the surface of the nasal polyp with a brush (Copan) for 30 seconds, rotate 3-4 times, brush the surface of the polyp, and place the brush in the lysate , Short-term storage at 4 ° C (not more than 24 hours), or transfer to long-term storage below -20 ° C.
  • a brush Copan
  • a method for detecting the expression of CLC gene in nasal exfoliated cells comprising the following steps:
  • Step 1 Extract RNA from the nasal cavity exfoliated cells: Add 20mL RNA extraction solution to the centrifuge tube containing the nasal cavity exfoliated cells, dissolve and shake, and let stand at room temperature for 7min; add 10mL of chloroform, shake and mix, and leave at room temperature for 7min Centrifuge at 5 ° C, 14000r / min for 20min; take 20mL of supernatant, add 20mL of isopropanol, mix well and let stand for 12min, centrifuge at 5 ° C, 14000r / min for 20min, discard the supernatant, and retain the first precipitate; 40 mL of 90% ethanol was added to the first pellet, centrifuged at 14000 r / min for 3 min at 5 ° C, the supernatant was discarded, and the second pellet was retained; the centrifuge tube was capped, and centrifuged at 5 ° C, 14000 r / min for 3 min After removing the supernatant, let it stand for 20 minutes,
  • Step 2 The steps for preparing cDNA by reverse transcription are the same as in Example 7.
  • Step 3 The preparation of the real-time quantitative PCR reaction solution in the real-time quantitative PCR amplification detection step is the same as in Example 7.
  • the standard three-step method for PCR amplification is adopted.
  • the reaction conditions of the standard three-step PCR standard procedure include The following steps: Phase 1: Pre-denaturation at 95 ° C for 2 minutes; Phase 2 PCR reaction: Reaction at 95 ° C for 1 minute, at 55 ° C for 1 minute, at 72 ° C Under the conditions, the reaction was performed for 1 minute, and thus 40 cycles were performed; finally, 72 ° C, 7 minutes of annealing extension.
  • Step 4 Calculate the expression level of the CLC gene:
  • the expression of CLC in this patient was 0.19 times (1/2 2.4 ) of GAPDH.
  • the patient was instructed to flush the nasal cavity with normal saline, and under a nasal endoscope, press the surface of the nasal polyp with a brush (Copan) for 30 seconds, rotate 3-4 times, brush the surface of the polyp, and place the brush in the lysate , Short-term storage at 4 ° C (not more than 24 hours), or transfer to long-term storage below -20 ° C.
  • a brush Copan
  • a method for detecting the expression of CLC gene in nasal exfoliated cells comprising the following steps:
  • Step 1 Extract RNA from nasal cavity exfoliated cells. Add 0.1mL RNA extraction solution to the centrifuge tube containing nasal exfoliated cells, dissolve and shake, and let stand at room temperature for 7min. Add 0.03mL of chloroform, shake and mix, and leave at room temperature.
  • Step 2 The steps for preparing cDNA by reverse transcription are the same as in Example 7.
  • Step 3 The preparation of the real-time quantitative PCR reaction solution in the real-time quantitative PCR amplification detection step is the same as in Example 7.
  • a standard three-step method for PCR amplification is adopted.
  • the reaction conditions of the standard three-step PCR standard procedure include The following steps: Phase 1: Pre-denaturation at 95 ° C for 2 minutes; Phase 2 PCR reaction: Reaction at 95 ° C for 1 minute, at 55 ° C for 1 minute, at 72 ° C Under the conditions, the reaction was performed for 1 minute, and thus 40 cycles were performed; finally, 72 ° C, 7 minutes of annealing extension.
  • Step 4 Calculate the expression level of the CLC gene:
  • An ELISA kit for detecting chronic sinusitis with nasal polyp subtypes comprising the following components:
  • An enzyme-labeled plate coated with Charcoalden's crystal protein CLC antibody which is coated with a Charcoalden's crystal-protein CLC antibody, which is a mouse anti-human CLC monoclonal antibody.
  • the coating amount of Charcoalden's crystal protein CLC antibody in the well was 0.5 ⁇ g;
  • Standard dilution phosphate buffered saline solution containing 1% Tween 20 and 10% bovine serum albumin;
  • Detection solution A working solution: Diluted to 5 ⁇ g / mL biotin-labeled human CLC antibody with standard dilution;
  • Detection solution B working solution anti-biotin-conjugated horseradish peroxidase diluted with a standard diluent to a concentration of 1.25 / mL;
  • Washing solution a phosphate buffered saline solution containing 0.05% Tween 20.
  • a method for preparing the above ELISA kit for detecting chronic sinusitis with nasal polyp subtypes includes the following steps:
  • Step 1 Prepare CLC antibody coated with Charcoalden's crystal protein:
  • Step 1 Animal immunization: take human recombinant CLC protein 1: 1, add Freund's complete adjuvant and Freund's incomplete adjuvant, mix the antigen and adjuvant in equal volumes, and grind them into a water-in-oil chyle.
  • the dose is 50 ⁇ g, and intraperitoneal injection.
  • Step 2 Cell fusion:
  • mice that have been immunized are taken, blood is collected from the eyeballs, and serum is separated as a positive control serum for antibody detection. At the same time, the mice were immersed in 75% alcohol for 5 minutes. The spleen was removed from the petri dish and placed in a dish containing 10 mL of incomplete culture medium. The surrounding connective tissue was washed and peeled off. The syringe core was ground into a cell suspension and counted, so that the spleen cells entered the incomplete medium in the dish, and pipetted several times with a pipette to make a single cell suspension, 1 ⁇ 10 8 -2.5 ⁇ 10 8 per mouse Splenic cells
  • Each hybridoma cell is aliquoted into a 96-well plate with a volume of 100 ⁇ L per well;
  • the antibodies can be detected by the visible clones; observe under an inverted microscope, mark the wells where only a single clone grows, and take the supernatant for antibody detection;
  • Step 3 Identification of Ig and subclasses of monoclonal antibodies:
  • HRP horseradish peroxidase
  • mice are inoculated intraperitoneally with paraphyllane or liquid paraffin, 0.3-0.5mL per mouse;
  • the hybridoma cells diluted with PBS or serum-free medium are inoculated intraperitoneally, and each mouse is 5 ⁇ 10 5 /0.2mL;
  • Step 2 Prepare samples: serum or plasma (EDTA or heparin anticoagulation): 1000g, centrifuge at 4 ° C for 15 minutes, take the supernatant, freeze and store in -80 ° C refrigerator, set aside; other body fluids (tissue homogenate, sputum, nasal secretion) Materials, various joint cavity fluids, etc.): 1000g, centrifuge at 4 ° C for 15 minutes, take the supernatant, and store it frozen in -80 ° C refrigerator for future use;
  • serum or plasma EDTA or heparin anticoagulation
  • Step 3 Prepare an enzyme-labeled plate coated with Charcoalden's crystal protein CLC antibody: Take a 96-well microplate and add 100 ⁇ L of diluted mouse anti-human CLC monoclonal antibody to each well, overnight at 4 ° C. Dilute the concentrated washing solution 30 times with distilled water to prepare a washing solution. After discarding the supernatant, add 300 ⁇ L to each well, wash it for 2 minutes, discard it, and drain it on absorbent paper. Repeat this twice, and add 250 ⁇ L to each well. Blocking solution, discarding the supernatant again and repeating the above plate washing step; the blocking solution includes a phosphate buffered saline solution containing 2% Tween 20 and 2% bovine serum albumin;
  • Step 4 Prepare the standard: take the standard recombinant CLC protein dry powder and place it at room temperature for 30min, and then dissolve it with 1mL of the standard dilution solution, repeat the mixing, and leave it for 10 minutes.
  • the dissolved standard is configured as a standard with a concentration of 20ng / mL. Marked as Standard 1, mark 6 to 6 EP tubes, and add 500 ⁇ L of the standard diluent, and then take 500 ⁇ L of liquid from the tube of Standard 1, add it to the tube of Standard 2, and mix. Take 500 ⁇ L of liquid from standard 2 tube and add to standard 3 tube. Follow this operation to standard 7 tube.
  • the final concentration obtained is 20ng / mL, 10ng / mL, 5ng / mL, 2.5ng / mL, Multiple dilution standards of 1.25ng / mL, 0.625ng / mL and 0.312ng / mL;
  • Step five sample dilution: take the sample to room temperature, dilute the serum or plasma sample with the standard dilution solution twice and test;
  • Step 6 Sample loading: Take the enzyme-labeled plate coated with Charcoalden's crystal protein CLC antibody prepared in step 3, and add 100 ⁇ L of the standard dilution after step 4 and the dilution after step 5 to each well. At the same time, set a blank well to which the standard diluent is added, attach the lid, and wash the plate 3 times after incubating at 37 ° C for 2 hours;
  • Step 7 Prepare working solution of detection solution A: Take biotin-labeled human CLC antibody and dilute it to 5 ⁇ g / mL with standard dilution solution, add 100 ⁇ L to each well of the microplate, cover with membrane and incubate at 37 ° C. Wash the plate 3 times for 1 hour;
  • Step 8 Prepare working solution for detection solution B: Dilute to a concentration of 1.25 ⁇ g / mL of anti-biotin antibody-conjugated horseradish peroxidase using a standard diluent, and add 100 ⁇ L to each well of the microtiter plate. Cover the membrane and incubate at 37 ° C for 0.5 hours, and wash the plate 5 times;
  • Step 9 Color development: Take TMB solution and add equal volume of 0.75% hydrogen peroxide to prepare TBM substrate coloring solution. Add 90 ⁇ LTBM substrate coloring solution to each well of the microplate, and incubate at room temperature for 15-30 hours, protected from light. Min. After observing that the wells containing the standard with a concentration of Xng / mL turn brown, add 50 ⁇ L of stop solution 2N sulfuric acid to each well of the microtiter plate, and wait to add the wells with the standard of Xng / mL. When the color changes from yellow to blue, the detection wavelength is 450nm using a microplate reader, and the reference wavelength is 550nm-570nm. The standard curve is made in 4-pl mode and the sample concentration value is calculated.
  • Test method enzyme-linked immunosorbent assay (ELISA), the first line of each cell is the original OD value (absorbance value), the second line is subtracted from the blank control OD value (absorbance value), the third line corresponds to the actual OD value concentration.
  • the samples in the first column are standard samples of different concentrations, and the samples in the second to sixth columns are test secretion samples. Based on the data, the actual sample concentration of each secretion can be obtained.
  • the ELISA kit provided by the present invention can be used to detect chronic rhinosinusitis with nasal polyp subtype, sample 3B (3 is column B is row, the same below), 6B, 3C, 3D, 4D No CLC was detected in 6D, 3E, 5E, 3F, 5F, 6F, 3G, 4G, 5G, 6G, 3H, 4H, 5H. It is considered to be nasal polyps without eosinophil infiltration.
  • the present disclosure provides a kit for detecting chronic sinusitis with nasal polyp subtypes.
  • the proteomics and transcriptomics methods are used to select the CLC gene as a biomarker and apply it to the kit to realize the use of the reagent.
  • the kit is used to detect chronic sinusitis with nasal polyp subtypes, so that the final obtained kit includes specific primers for the CLC gene. Based on the specific primers, the kit of the present disclosure can quickly identify nasal polyp subtypes, and is more accurate than traditional pathological detection methods.
  • the kit can simultaneously perform large-scale, rapid Testing, saving labor costs and medical treatment costs. And the systematic kit has high identification accuracy, which can fully reflect the histopathological characteristics.
  • the kit provided by the present disclosure can detect nasal polyp cells from the surface of the nasal polyp by brushing or sticking, so as to determine the chronic sinusitis of the patient with nasal polyp subtypes, thereby avoiding wounds to the patient.
  • the safety of patient examination is improved, the operation is more convenient, and the labor cost and medical treatment cost are saved.
  • the method for detecting the expression of CLC gene in nasal exfoliated cells uses the effectively screened CLC gene as a biomarker to provide a method for detecting the expression of the gene and realize the calculation of CLC gene expression in nasal exfoliated cells. It can effectively obtain the expression level of CLC gene, and the method provided is simple and fast, high sensitivity, good reproducibility, and is suitable for wide application.
  • the present disclosure provides a method for detecting the expression of CLC gene in exfoliated nasal cells, wherein the CLC gene is a lysophospholipase expressed in eosinophils and basophils. It hydrolyzes lysophosphatidylcholine into glycerophosphocholine and free fatty acids.
  • the protein may have carbohydrate or IgE binding activity. It is structurally and functionally related to the galectin family of ⁇ -galactoside-binding proteins. It is related to inflammation and some myeloid leukemias. Diseases associated with CLC include autoinflammation, dyslipidemia, and dermatological syndrome.
  • the disclosed method for the expression of CLC gene in nasal exfoliated cells can be used to detect the expression of CLC in nasal exfoliated cells.
  • the method for detecting the expression level of CLC gene in nasal exfoliated cells adopts a relative quantitative method of ⁇ Ct or 2- ⁇ Ct method according to actual needs, selects a reference gene with a relatively constant expression amount, and standardizes the number of internal reference genes by The difference between the Ct value of the target gene of the sample and the internal reference gene is calculated to calculate the expression amount of the target gene.
  • the method is simple and fast, the detection accuracy is high, the detection cost can be reduced, and the detection time can be saved. The result is easy to interpret and so on. Greatly improved the experimental efficiency.
  • the method for detecting the expression level of CLC gene in nasal exfoliated cells provides a basis for future gene screening technology for chronic sinusitis subtypes with nasal polyps, and provides a reliable basis for clinical guidance and drug treatment.
  • the feasibility of the kit for detecting chronic sinusitis subtype with nasal polyps in clinical application is guaranteed.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un kit de détection d'une sinusite chronique avec un sous-type de polypes nasaux et une application d'un gène ou d'une protéine CLC en tant que biomarqueur, un procédé de détection d'une quantité d'expression de gène CLC dans des cellules exfoliées de cavité nasale et une application, et un kit ELISA de détection d'une sinusite chronique avec un sous-type de polypes nasaux et un procédé de préparation associé. La présente invention concerne en outre l'utilisation d'un gène ou d'une protéine CLC en tant que biomarqueur pour détecter une sinusite chronique avec un sous-type de polypes nasaux. Le procédé de détection de sinusite chronique avec le sous-type de polypes nasaux selon la présente invention comprend la mesure d'une quantité d'expression de gène CLC à l'aide d'une PCR d'une amorce spécifique du gène CLC, en particulier une PCR quantitative fluorescente en temps réel, ou la mesure d'une quantité d'expression de protéine CLC à l'aide d'un anticorps anti-CLC, en particulier un ELISA d'un anticorps monoclonal de souris anti-CLC humain.
PCT/CN2019/093299 2018-07-03 2019-06-27 Procédé et kit de détection de sinusite chronique avec un sous-type de polypes nasaux et l'application d'un gène ou d'une protéine clc en tant que biomarqueur Ceased WO2020007230A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201810719334.2 2018-07-03
CN201810717444.5 2018-07-03
CN201810717444.5A CN108707661B (zh) 2018-07-03 2018-07-03 Clc基因的特异性引物在制备用于检测慢性鼻窦炎伴鼻息肉亚型的试剂盒的应用
CN201810719334.2A CN108977510A (zh) 2018-07-03 2018-07-03 检测鼻腔脱落细胞中clc基因表达量的方法及应用
CN201811437289.8 2018-11-28
CN201811437289.8A CN109709329A (zh) 2018-11-28 2018-11-28 用于检测慢性鼻窦炎伴鼻息肉亚型的elisa试剂盒及其制备方法

Publications (1)

Publication Number Publication Date
WO2020007230A1 true WO2020007230A1 (fr) 2020-01-09

Family

ID=69060108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/093299 Ceased WO2020007230A1 (fr) 2018-07-03 2019-06-27 Procédé et kit de détection de sinusite chronique avec un sous-type de polypes nasaux et l'application d'un gène ou d'une protéine clc en tant que biomarqueur

Country Status (1)

Country Link
WO (1) WO2020007230A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017144894A1 (fr) * 2016-02-26 2017-08-31 Ucl Business Plc Procédé de détection de la tuberculose active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017144894A1 (fr) * 2016-02-26 2017-08-31 Ucl Business Plc Procédé de détection de la tuberculose active

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CALAFAT: "Ultrastructural localization of Charcot -Levden crystal motein in human eoiinophik and basophils", EUR J HAERNATOL, 31 December 1997 (1997-12-31) *
J ENNIFER LAVING: "Superior turbinate eosinophilia correlates with olfactory deficit in chronic rhinosinusitis patients", LARYNGOSCOPE, 31 October 2017 (2017-10-31), XP55672505 *
JENNIFER LAVING: "Superior turbinate eosinophilia correlates with olfactory deficit in chronic rhinosinusitis patients", LARYNGOSCOPE, 31 October 2017 (2017-10-31), XP055672505 *

Similar Documents

Publication Publication Date Title
Schwaderer et al. Polymorphisms in α-Defensin–encoding DEFA1A3 associate with urinary tract infection risk in children with vesicoureteral reflux
US20170283789A1 (en) Methods for collecting cervical-vaginal fluids and isolating exosome and microvesicles for molecular analysis
JP2018527590A (ja) トリプトファニルｔＲＮＡ合成酵素を利用した感染症又は感染合併症の診断用組成物と診断マーカー検出方法
CN103695532B (zh) 广州管圆线虫病早期检测的分子标记物及引物
CN116042902A (zh) 一种同时检测六种念珠菌的实时荧光核酸恒温扩增检测试剂盒及其专用引物和探针
WO2026017138A1 (fr) Biomarqueur pax5 pour maladies associées à une septicémie et son utilisation
CN105779598B (zh) 一种诊治垂体瘤的分子标志物
Liang et al. Potential of metagenomic next-generation sequencing in detecting infections of ICU patients
Shi et al. Metagenomic next-generation sequencing vs. conventional detection methods for detecting the pulmonary infections.
CN108913762A (zh) 用于检测慢性鼻窦炎伴鼻息肉亚型的试剂盒及cst1基因作为生物标志物的应用
CN105907881A (zh) 基因标志物在制备诊断缺血性脑卒中的产品中的用途
WO2020007230A1 (fr) Procédé et kit de détection de sinusite chronique avec un sous-type de polypes nasaux et l'application d'un gène ou d'une protéine clc en tant que biomarqueur
CN108707661B (zh) Clc基因的特异性引物在制备用于检测慢性鼻窦炎伴鼻息肉亚型的试剂盒的应用
Sonkar et al. Evaluation of DNA based techniques for the diagnosis of human vaginal trichomoniasis in North Indian population
El-Morsy et al. Allergic fungal rhinosinusitis: detection of fungal DNA in sinus aspirate using polymerase chain reaction
US11397178B2 (en) Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy
CN109988830A (zh) 一种用于脓毒症标志物的lncRNA及其应用
CN108949954A (zh) 用于检测慢性鼻窦炎伴鼻息肉亚型的试剂盒及alox15基因作为生物标志物的应用
CN116377058A (zh) 一种圆锥角膜的检测panel及其应用
WO2020007227A1 (fr) Procédé et kit de détection d'une rhino-sinusite chronique avec un sous-type de polypes nasaux et utilisation du gène alox15 en tant que biomarqueur
CN105597109A (zh) 原发骨肉瘤的诊治分子标记
CN111440859A (zh) 一种人呼吸道合胞病毒感染的生物标志物及应用
US20200172975A1 (en) Cell-Free microRNA Signatures of Pancreatic Islet Beta Cell Death
US20220220557A1 (en) Use of Cystatin SN in Detecting Chronic Rhinosinusitis with Nasal Polyps Subtype and Predicting Sensitivity of Patient to Glucocorticoid
CN108624696A (zh) 分子标记在制备静脉内平滑肌瘤病诊断检测产品中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19830882

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19830882

Country of ref document: EP

Kind code of ref document: A1